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Abstract
Stem cell technology has gained considerable recognition since its inception to advance
disease modeling and drug screening. This is especially true for tissues that are difficult to study
due to tissue sensitivity and limited regenerative capacity, such as the heart. Previous work in stem
cell-derived cardiac tissue has exploited how we can engineer biologically functional heart tissue
by providing the appropriate external stimuli to facilitate tissue development. The goal of this
dissertation is to explore the potentials of stem cell cardiac organoid models to recapitulate heart
development and implement analytical computational tools to study cardiac physiology. These
new tools were implemented as potential advancements in drug screening applications for better
predictions of drug-related cardiotoxicity.
Cardiac organoids, generated via micropatterning techniques, were explored to determine
how controlling engineering parameters, specifically the geometry, direct tissue fate and organoid
function. The advantage of cardiac organoid models is the ability to recapitulate and study human
tissue morphogenesis and development, which has currently been restricted through animal
models. The cardiac organoids demonstrated responsiveness manifested as impairments to tissue
formation and contractile functions as a result of developmental drug toxicity. Single-cell genomic
characterization of cardiac organoids unveiled a co-emergence of cardiac and endoderm tissue,
which is seen in vivo through paracrine signaling between the liver and heart. We then
implemented computational tools based on nonlinear mathematical analysis to evaluate the cardiac
physiological drug response of stem cell-derived cardiomyocytes. This dissertation discusses in
vitro tissue platforms as well as computational tools to study drug-induced cardiotoxicity. Using
these tools, we can extend current toolboxes of understanding cardiac physiology for advanced
investigations of stem-cell based cardiac tissue engineering.
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List of Figures
Figure 1. Stem cell biology and human development. Potentials of using in vitro induced
pluripotent stem cell biology to model in vivo human cell and tissue development.
Figure 2. Stem cell organoids exhibiting spatial-organization and features that resemble
native in vivo organs. Stem cell organoids with spatial organization and patterning have been
engineered to model numerous organs including (a) brain39, (b) kidney59, (c) intestinal42, and (d)
retinal43. All figures reproduced with copyright permissions.
Figure 3. Stem cell organoids engineered through precise microenvironment control. (a)
Intestinal organoids generated in synthetic PEG-4MAL hydrogels46; (b) microfluidic-controlled
epiblast and amnion structures60; (c) micropatterning of human stem cells to model germ layer
formation49. All figures reproduced with copyright permissions.
Figure 4. Cardiac organoids derived from cardiomyocytes differentiated from human
induced pluripotent stem cells. Various cardiac organoid models have been developed by
researchers. (a) Vascularized cardiac organoid17; (b) self-organized cardiac organoid
microchamber54. All figures reproduced with copyright permissions.
Figure 5. Schematic of procedure and process of PDMS stencil fabrication
(a) Schematic outlining key steps of the entire procedure. (b) SU8 master with a small amount of
PDMS prepolymer. (c) Completed assembly of the patterned SU8 master-PDMS-transparencyglass slide construct. (d) Thin film of PDMS removed from the assembly after curing and then
placed on top of the (e) optically clear PEG grafted surface55. Figure reproduced from Hoang et
al. 2018 Nature Protocols.
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Figure 6. Quality control of patterned hiPSC pluripotency. The micropatterned hiPSC colonies
maintained the expression of pluripotency markers of (from left to right) OCT4, NANOG, Ecadherin, SOX2, and SSEA4. Scale bar, 200 µm.
Figure 7. Confluent micropatterned hiPSC colonies. Bright-field microscopy images of arrays
of micropatterned hiPSCs with different sizes and shapes. Scale bar, 400 µm. Clockwise: 200 µm
circles, 400 µm circles, triangles, and 600 µm circles.
Figure 8. Cardiac differentiation timeline to generate cardiac organoids. Patterned cell
morphology changes from 2D monolayer of cells (D0) into 3D tissue (D6 onward) throughout
differentiation; scale bars 600 µm.
Figure 9. Cardiac organoid function and structure characterization. (a) Motion tracking
analysis based on vector computation of pixel movement generates contraction velocity
waveforms representing beat cycles of the cardiac organoids. (b) Immunofluorescence staining
used to compute the Area Ratio, which is the area of cardiac tissue (cTnT) coverage relative to the
area of the entire pattern. (c) Confocal imaging was used to capture z-stacks of the tissues, which
were reconstructed for 3D morphological scoring of the height and full-width at half-maximum
(FWHM). Scale bars 200 µm.
Figure 10. Differentiation from pluripotency into cardiac organoids. (a) 24h after CHIR
treatment, patterned hiPSCs express mesodermal marker brachyury. (d) On Day 8 of
differentiation, cardiac organoids express ISL1, followed by (d) NKX2.5 and GATA4 on Day 10,
indicative of early cardiac progenitor cells; scale bars 200 µm. (b – top row) The spatial-organized
cardiac organoids showed cardiac muscle on the top center with cardiomyocyte-specific proteins
(cardiac troponin T (cTnT), β myosin heavy chain (MHC-β) sarcomeric α-actinin and cardiac
troponin I (cTnI)) and smooth muscle-like cells on the perimeter of the organoids with stromal cell
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markers (smooth muscle actin (α-SMA), calponin, transgelin (α-SM22) and vimentin). Scale bar,
200 µm. (b – bottom row) confocal microscopy images of cardiomyocytes on the cardiac
organoids. Scale bar, 50 µm.
Figure 11. Geometry effect on cardiac organoid function and structure. (a) Confocal
reconstructions of cardiac organoids generated in circular, triangular, and square shapes; scale bars
200 µm. From comparison of contraction function of cardiac organoids as influenced by shape
geometry, (b) triangular and square organoids exhibited significantly decreased contraction
velocity (n ≥ 10, *p = 0.0024), but (c) significantly faster beat rate (n ≥ 9, *p ≤ 0.0001) with (d)
longer beat duration (n ≥ 9, *p ≤ 0.0001) relative to circular organoids. Structural 3D
morphological scoring of cardiac organoids showed that circle shapes produced organoids that
were significantly larger in area ratio (n ≥ 16, *p ≤ 0.0001) than triangle and square organoids.
Only triangle organoids produced significantly decreased tissue height (n ≥ 9, *p = 0.0013) and
both triangular and square organoids had significantly smaller FWHM (n ≥ 9, *p ≤ 0.0001). (h)
Structure-function correlation plot illustrating the effect of structure on cardiac contraction. (i)
Structure-structure correlation plot illustrating shape influence on 3D architecture. In all panels,
box plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical
analysis was performed based on analysis of variance (ANOVA) with Tukey’s multiple
comparison test.
Figure 12. Pattern size effects on cardiac organoid characteristics. (a) Cardiac organoids
generated from the circular patterns with different sizes (200 µm – 1000 µm in diameter) showed
spatial-organization of cardiomyocytes and stromal cells and 3D dome-shape in the X-Z plane.
Scale bar, 200 µm. Contractile motion analysis showed no significant differences in contraction
velocity amongst the cardiac organoids generated from different pattern sizes, but 200-µm patterns
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generated the organoids with significant differences in beat rate and beat duration comparing to
the other pattern sizes (n = 10, *p < 0.0001 for beat rate; *p < 0.0001 for beat duration). The area
ratio between cardiomyocyte staining and entire pattern size showed significant larger coverage
but higher variation in cardiac muscle differentiation on the cardiac organoids generated from the
patterns with 200 µm, 800 µm and 1000 µm diameter (n = 9, *p ≤ 0.0001 between 200 µm and
400/600 µm; *p ≤ 0.0001 between 400/600 and 800/1000 µm). The cardiac organoids generated
from 600-µm diameter circles exhibited better 3D morphology with largest values in (f) height (n
= 8, *p = 0.0126 between 200 µm and 600 µm; *p = 0.0126 between 600 and 800/1000 µm) and
(g) FWHM (n = 8, *p ≤ 0.0001 between 600 µm and 200/400 µm; *p ≤ 0.0001 between 600 and
800/1000 µm). (h) Structure-function correlation plot for the cardiac organoid generated from
different pattern sizes showed close clustering of the circular patterns of 400 – 1000 µm diameters,
except for 200 µm diameter. (i) Structure-structure correlation plot showed that 600-µm diameter
circular pattern consistently produced the cardiac organoids with the largest 3D structure. (j) Gene
expression analysis showed that larger pattern sizes (600 µm and 1000 µm diameter circles) were
associated with high expression of cardiac muscle-related genes, while small pattern (200 µm
diameter circle) was associated with high expression of stromal-related genes. In all panels, box
plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical analysis
was performed based on analysis of variance (ANOVA) with Tukey’s multiple comparison test.
Figure 13. Gene expression patterns directed by pattern size. (a) Gene expression heatmap of
104 genes assayed the cardiac organoids generated from 200 µm, 600 µm, and 1000 µm – diameter
circular patterns. (b) Gene expression of cardiac-specific and smooth muscle/stromal genes
normalized to the expression of GAPDH housekeeping gene. (c) The signaling-related genes
showed highly differentiated expression.
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Figure 14. Cardiac organoid developmental toxicity to doxylamine succinate and
thalidomide. (a) The timeline of cardiac organoid generation and continuous drug exposure. Epifluorescent microscopy images of the cardiac organoids for comparison between untreated controls
with (b) doxylamine succinate (category A drug) and (c) thalidomide (category X drug). The area
ratio of cardiac muscle coverage showed (d) an increase with doxylamine succinate (n = 29, *p ≤
0.0001), but a decrease with thalidomide at high concentrations (n ≥ 28, *p ≤ 0.0001). The
contraction velocity of cardiac contractile motion showed no drug effect from (f) either
doxylamine succinate (g) or thalidomide. The beat rate showed (h) a decrease with doxylamine
succinate (n ≥ 9, *p ≤ 0.0001), and an increase with thalidomide at 1 µM and 10 µM concentrations
(n ≥ 12, *p ≤ 0.0001). (j) The cardiac organoids under doxylamine succinate exposure showed no
drug effects on the 3D organoid morphology at all the tested concentrations. (k) Thalidomide
exposure induced significant structural impairment on 3D organoid formation, showed as lower
height (n ≥ 9, *p ≤ 0.0001) and FWHM (n ≥ 14, *p ≤ 0.0001) at high concentrations. Representative
confocal microscopy images of the cardiac organoids of (k) untreated control and (m) 100 µM
thalidomide exposure showed severe abnormal organoid formation for quantitative morphological
scoring.
Figure 15. Developmental toxicity assay of cardiac organoids in response to treatment with
Amoxicillin (Category B). Amoxicillin showed moderate toxicity with decreased beat rate (twoway student t-test, n ≥ 11, *p = 0.0048) and increased beat duration (two-way student t-test, n ≥
11, *p = 0.0013) at high concentrations. Amoxicillin treatment at low concentrations, however,
produced smaller cardiac tissues in area ratio (two-way student t-test, n ≥ 18, *p = 0.0083 between
Controls and 1 µM) and in height (two-way student t-test, n ≥ 7, *p ≤ 0.0001).
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Figure 16. Developmental toxicity assay of cardiac organoids in response to treatment with
Rifampicin (Category C). In all assays, cardiac organoids failed to differentiate at 100 µM
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 12,
*p = 0.0174), beat rate (two-way student t-test, n ≥ 12, *p = 0.0232), area ratio (two-way student
t-test, n = 29, *p = 0.0123), height (two-way student t-test, n ≥ 10, *p ≤ 0.002 relative to controls)
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001).
Figure 17. Developmental toxicity assay of cardiac organoids in response to treatment with
Doxycycline (Category D). In all assays, cardiac organoids failed to differentiate at 100 µM
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 7, *p
= 0.0036), beat rate (two-way student t-test, n ≥ 7, *p ≤ 0.0067), beat duration (two-way student ttest, n ≥ 7, *p ≤ 0.0001), and height (two-way student t-test, n = 8, *p ≤ 0.0061 relative to controls)
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001).
Figure 18. Developmental toxicity assay of cardiac organoids in response to treatment with
Lithium carbonate (Category D). No significant toxicity effects were seen in any contraction
function. However, moderate toxicity was seen in all concentrations for the area ratio (ANOVA,
n ≥ 26, *p ≤ 0.0001) and in FWHM (ANOVA, n ≥ 20, *p ≤ 0.0001) relative to the controls.
Figure 19. Developmental toxicity assay of cardiac organoids in response to treatment with
Phenytoin (Category D). Phenytoin showed no contractile functions at 100 µM concentration,
with moderate effects at 1 µM on beat rate (two-way student t-test, n ≥ 11, *p = 0.0165) and beat
duration (two-way student t-test, n ≥ 11, *p = 0.0101). Organoids were also smaller in area ratio
at 10 µM treatment (two-way student t-test, n = 28, *p = 0.0006) and smaller at all concentrations
in height (ANOVA, n ≥ 12, *p ≤ 0.0001) and FWHM (ANOVA, n=20, *p ≤ 0.0001) relative to
controls.
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Figure 20. Developmental toxicity assay of cardiac organoids in response to treatment with
Tretinoin (Category D). Cardiac tissue failed to develop at 10 µM concentrations with no
contraction functions. Contraction velocity was lower at 0.1µM (two-way student t-test, n ≥ 7, *p
= 0.0274), whereas beat rate was faster at 0.1µM and 1 µM (ANOVA, n ≥ 7, *p = 0.0001). Beat
duration was significantly lower at 1 µM (two-way student t-test, n ≥ 7, *p ≤ 0.0001) as well. Low
concentration of 0.1 µM also showed toxic effects on area ratio (two-way student t-test, n ≥ 12, *p
≤ 0.0112), height (two-way student t-test, n ≥ 8, *p = 0.0004), and FWHM (two-way student ttest, n ≥ 12, *p ≤ 0.0001).
Figure 21. Developmental toxicity assay of cardiac organoids in response to treatment with
Isotretinoin (Category X). Cardiac tissue failed to develop at 1 µM and 10 µM concentrations
with no contraction functions. Low concentration of 1 µM resulted in faster beat rate (two-way
student t-test, n ≥ 13, *p ≤ 0.0007) and smaller area ratio (two-way student t-test, n ≥ 31, *p ≤
0.0001). However, high concentrations produced organoids that were significantly taller in height
(ANOVA, n ≥ 9, *p ≤ 0.0001) and larger in FWHM (ANOVA, n ≥ 12, *p ≤ 0.0001).
Figure 22. Cardiac looping scored as a cardiac developmental toxicity evaluation in the
zebrafish whole embryo culture assay (zWEC). Zebrafish embryo heart structures were scored
based on loop structure, where (a) D-looped heart structures are the normal expected structure. No
significant drug effect from (b) doxylamine succinate exposure, and a very mild toxicity level from
high dosage exposure of (c) thalidomide. A sample size of n>40 embryos were analyzed for these
treatment groups.
Figure 23. Zebrafish whole embryo culture (zWEC) assay of cardiac looping for seven drug
compounds. (a) Category B amoxicillin and (b) Category C rifampicin produced mild
developmental toxic effect. (c-f) Category D drugs displayed developmental toxic effects ranging

xvii

from moderate (lithum carbonate, phenytoin, and doxycycline) to severe (tretinoin). (g) Category
X isotretnoin produced severe developmental toxic effects at all concentrations. (h) Morphological
scoring was performed on heart structures of developing zebrafish embryos based on either normal
(D-loop), reverse (L-loop), no loop, or no score where the heart did not express GFP and/or fall
into the previous three categories. A sample size of n>19 embryos was used for all treatment
groups.
Figure 24. Single-cell RNA sequencing and bioinformatics workflow. (a) Single-cell RNA
sequencing pipeline using 10X Genomics from sample preparation to data output using
CellRanger. Single cell data is plotted as a series of violin plots for quality control. Quality control
of output data involves filtering of (b) read counts, (c) detected features, and (d) percent
mitochondrial counts. Single cell data is then clustered into cell types based on PCA
dimensionality reduction and visualized using (e) t-SNE and (f) trajectory trees to identify cell
types.
Figure 25. Cell-specific gene identification of cardiomyocytes and stromal cells. (a)
Cardiomyocytes were identified by locating the cell cluster expressing cardiomyocyte markers
ACTN2, MYBPC3, and MYH6. (b) MYH6 expression showed to be highly specific to clusters 1
and 7, identifying two sub-populations of cardiomyocytes. (c) Stromal cell markers TAGLN2 and
ACTA2 confirmed the presence of stromal cells and (d) displayed scattered expression across
multiple cell clusters, except in the cardiomyocyte populations.
Figure 26. Heat map of top one hundred differentially expressed genes for cell cluster
classification. Genes were filtered to only include the top 100 genes with the highest variance.
These differentially expressed genes were used to approximate the classification of the cell type
composing each cluster.
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Figure 27. Integrated t-SNE plot of classified cell clusters composing 200 µm, 600 µm, and
1000 µm cardiac organoids. t-SNE plot of more than 63,000 cells colored by cell type. Cells were
clustered based on PCA and graph-based clustering.
Figure 28. Classification of cell clusters using trajectory analysis and identification of cellspecific genes. (a) Trajectory analysis of cardiac organoids of different sizes fall in three primary
cell lineage branches: cardiac, stromal, and endodermal. (b) Lineage specific markers were
mapped to locate and further classify the cell populations illustrated within the t-SNE.
Figure 29. The t-SNE expression maps for vasculogenic, cardiogenic, and hepatogenic
signaling factors in the cardiac organoids. Cardiac organoids showed low indication of
vasculogenesis, but high indication of paracrine signaling between mesodermal cardiac lineages
and endodermal hepatic lineages
Figure 30. Fractional composition of cell types in small, mid-size, and large organoids.
Cardiac organoids of different sizes drives differential cell specification. Small organoids (200
micron) had higher fractional compositions of early cell types and progenitor cells. Mid-size
organoids (600 micron) had the highest fraction of cardiomyocytes and smooth muscle cells. Large
organoids (1000 micron) had the highest fraction of endodermal cells.
Figure 31. Heat map and pathway analysis of cardiac organoid cell types. Gene ontology
pathway analysis was performed using a range of 10-20 genes for each major cell cluster.
Figure 32. Cardiac, stromal, and endodermal gene expression patterns relative to cardiac
organoid size. Fold change expression patterns were plotted to compare gene expression across
the three pattern sizes. Genes were selected based on specificity to cardiac, endodermal, and
stromal cell lineages.
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Figure 33. Process workflow of hiPSC-CM contractile motion characterization. The
contractile motion of hiPSC-CMs was recorded as beating videos, which were analyzed using
motion tracking software to generate motion vectors and contractile motion waveforms. This data
was then analyzed using PSR to compute the dimensional parameters. The embedding dimension
characterizes the regularity of the contractile motions, which reflects the changes in beat rhythm
and overall gross motion. The fractal dimension characterizes the complexity, which reflects the
secondary aberrations present within each beat cycle128.
Figure 34. Reconstruction of cardiac motion waveforms into phase space. The phase spaces
of a regular (a) and a complex (c) cardiac contractile motions are plotted along with their
corresponding motion waveforms (b, d). The embedding dimensions from a single motion
waveform were computed from PSR to compare the differences in regularity between two
contractile motions (e). The regularity dimensions derived the embedding dimensions were plotted
with respect to τ (f). The average fractal dimension across all τ was computed from PSR (g) and
then plotted with respect to τ (h)128.
Figure 35. PSR analysis of secondary system aberrations. A motion waveform was supplied
with random noise ranging from 2.5%-50% (a), and corresponding phase space was reconstructed
to compute the dimensional parameters respectively for different degrees of noise. No significant
difference was found based on embedding and regularity dimensions among the contractile
motions with different noise level (b, c), but fractal dimensions exhibited significant increase with
the increase of the noise level (d, e)128.
Figure 36. PSR analysis of propranolol treated hiPSC-CMs. The application of propranolol to
hiPSC-CMs increased the average embedding dimension with the increase of drug concentrations,

xx

which correlated to a reduction in regularity dimension. No significant difference was found for
fractal dimension between baseline control and drug exposure128.
Figure 37. PSR analysis of E4031 treated hiPSC-CMs. E4031 induced significant increases in
the embedding and regularity dimensions between controls and drug exposure. High dosage of
E4031 (100 nM) induced a significant increase of fractal dimension on the hiPSC-CMs in
comparison to the control and low dosage128.
Figure 38. PSR analysis of metoprolol treated hiPSC-CMs. PSR analysis showed that treatment
of hiPSC-CM with metoprolol has no significant influence on the embedding, regularity and fractal
dimensions128.
Figure 39. PSR analysis of isoproterenol treated hiPSC-CMs. Low dosage of isoproterenol (50
nM) decreased the embedding dimension, which corresponded to a rise in the regularity of the
system. In contrast, high dosage of isoproterenol (10 µM) increased the embedding and fractal
dimensions, indicating the contractile motions of hiPSC-CMs gained aberrations but lost
regularity128.
Figure 40. Drug-induced arrhythmia comparison of motion tracking versus calcium flux.
Brightfield and fluorescence videos of drug-treated GCaMP6f hiPSC-CMs were recorded for (a)
motion tracking analysis and (b) calcium flux analysis. (c) Waveforms generated from each assay
were subjected to PSR analysis. PSR analysis of both methods illustrated the sensitivities to drug
interference by quantifying changes in the embedding and fractal dimensions as a result of (d)
isoproterenol and (e) propranolol induced-arrhythmias. All scale bars are 100 μm128.
Figure 41. Nonlinear reconstruction of time series contractile motion signals. (a) Contraction
motion waveforms were analyzed using phase space reconstruction to determine the fractal
properties of the signals, including two parameter capacity dimension and correlation dimension,
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which characterize the geometric space and distribution dynamics of the signals. (b) Two hiPSCCM clusters (Cluster A and Cluster B) exhibiting comparable contractile physiology, (c) which
were compared in time domain and respective nonlinear phase spaces. (d) The capacity dimension
with respect to time lag (τ) was comparable between the two clusters, (e) but the correlation
dimension with respect to embedding dimension (m) showed different trends. Scale bars = 100
μm129.
Figure 42. Contractile velocities of hiPSC-CMs exposed to drug compounds. Short term
changes to contraction motion waveform and average contraction velocities were observed in
hiPSC-CMs treated (a, d) alfuzosin, (b, e) flecainide and (c, f) isoproterenol. (g, h) Long-term
treatment of hiPSC-CMs with isoproterenol showed negligible changes in both contraction and
relaxation velocities over a 7-day period129.
Figure 43. Fractal changes on hiPSC-CM drug response. hiPSC-CMs was treated with 3 drugs,
including (a) alfuzosin, (b) flecainide and (c) isoproterenol over a short period with incremental
doses. The beat rate, capacity dimension and correlation dimension were compared respectively
in response to the drug dosages. (d) A long-term drug study was also conducted by supplying a
constant dose of isoproterenol over the course of 7 days129.
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1. Chapter 1: Introduction

1.1

Pluripotent stem cell engineering

Stem cells have emerged over the past decades as powerful tools in research. The field of stem cell
engineering encompasses many disciplines, including basic research, development of diagnostic
and screening tools, and development of stem cell-based therapies. More specifically, human
induced pluripotent stem cells (hiPSCs) have demonstrated promise in medical research fields.
hiPSCs are genetically reprogrammed adult cells with capabilities to develop into any cell type
with the proper induction factors. hiPSCs rose to prominence when Yamanaka et al. demonstrated
that adult somatic fibroblast cells can be reprogrammed to become pluripotent1. This allows the
cells to obtain unique characteristics that resemble embryonic stem cells (ESCs), which are found
in embryos and are the origin of human development. The ability to recapitulate ESC phenotypes
proposes tremendous potential to be implemented in in vitro modeling of cell and tissue
development, from differentiation to tissue morphogenesis. In addition, hiPSCs are self-renewing,
offering an unlimited source of cells that bypass controversies involved in ESC sourcing. These
characteristics offer great potential for implementation of hiPSC tissue development as an in vitro
model for in vivo human development (Figure 1).

1.2

Pluripotent stem cell-based cardiac tissue engineering

1.2.1 Advantages of pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
Diseases related to the heart are one of the most prominent worldwide. The extremely limited
regenerative potential of the makes it especially susceptible to damage and failure. Tissue
engineering approaches have been the strategy of interest for cardiac related regenerative
1

medicine. Progress in cardiac tissue models has demonstrated extensive opportunities to engineer
in vitro biologically optimized tissues for understanding disease mechanisms, formulating
personalized therapies, and developing drug-screening platforms2–6. Cardiomyocytes are the
primary cells that comprise the heart and are the main functional cells that produce heart
contraction. Cardiomyocytes for cardiac tissue engineering were traditionally obtained by isolation
from mammalian model organisms, most notably being from neonatal mouse or rat sources
(nrCMs). The limitations of these cells are that these sources require time consuming isolation
procedures each time the cells are needed. Additionally, primary cell isolation from rats presents
a species barrier that cannot be reliably translated to human cardiac physiology7,8. By deriving
cardiomyocytes from hiPSCs (hiPSC-CMs), we could continuously generate these highly
functional cells at an unlimited capacity because of the regenerative capacity of hiPSCs to
accelerate progress in this field.

1.2.2

hiPSC-CMs for drug screening

Drug-induced cardiac toxicity is one of the primary reasons for the failures of drug development
pipeline and even post-clinical removal due to cardiac side effects after reaching the market (Liang
et al., 2013). Recent advances in hiPSC technology have offered new insights into modeling
cardiac tissue in vitro and screening drug-induced cardiotoxicity. Neonatal rat cardiomyocytes
(nrCMs) are used as viable drug-screening platforms, but species differences present challenges in
fully recapitulating human physiology and drug response7. It has been shown that beat rhythm was
more stable in hiPSC-CMs compared to nrCMs, as well as high drug sensitivity and responsiveness
of hiPSC-CMs9. Treatment of hiPSC-CMs with norepinephrine and isoproterenol produced
changes in beat rate and contractility that was consistent with adult human heart slices, further
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suggesting the potential of hiPSC-CMs in screening for drug-induced cardiotoxicity10. With the
development of heart-on-chip technologies, pharmacological studies on the cardiac
microphysiological system showed that IC50 and EC50 values were more consistent with the data
from tissue-scale references compared to cellular-scale studies11.

1.2.3

hiPSC-CMs for three-dimensional cardiac tissue modeling

Accurate cardiac tissue modeling using three-dimensional (3D) stem cell-based cardiac tissue
engineering approaches primarily rely on direct cardiac differentiation from EBs12–14. EBmediated cardiac differentiation suffers from variability of EB size, organoid heterogeneity, and
poor spatial organization15. The majority of in vitro cardiac tissue models based on hiPSC-CMs
primarily focus on accurate recapitulation of physiologically relevant tissue structures of the adult
human heart, which are generally achieved by populating pre-fabricated 3D biomaterial scaffolds
with pre-differentiated hiPSC-CMs11,16–20. For example, in the biowire platform21, microfluidicbased devices22, and cantilever systems23, cardiomyocytes were first differentiated from
hiPSCs/hESCs in conventional tissue culture plates and then seeded as single cells or tissue
clusters into the fabricated devices to form adult-like aligned cardiac muscle11,24. hiPSC-CMs often
don’t exhibit phenotypes of mature cardiac tissue, because they are derived in vitro and are not
subjected to the same degree of time or biomechanical factors that promote maturation. Many
groups have focused on promoting 3D cardiac tissue alignment 3,11,16,20,25, which is a characteristic
of mature cardiac tissue. This is because cardiac alignment is essential for modulating the electrical
activity and population of cardiomyocytes to produce synchronized contraction function26. In
addition, disordered alignment is associated with congenital heart disease and cardiomyopathies27.
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The advantages of these engineered cardiac tissue models are not only the structural mimicry of
adult heart tissue, but also their capability of electromechanical measurements and simulations28,29.

1.3

Stem cell organoids

1.3.1

Stem cell organoids as models of dynamic tissue organization

The adult-mimicking cardiac tissue model systems described above are designed to enhance the
maturity and vascularization of hiPSC-CM tissues for the purpose of drug screening and disease
modeling21,30–32. However, they are not designed for studying dynamic cellular self-organization
occurring along with the cardiac differentiation process to study heart development since these
cells are seeded and reconstructed after differentiation. As such, these approaches do not allow us
to observe cell lineage specification and spatial self-organization during the cardiac development
process. The proper functioning of the heart is essential for embryo development and survival, as
it is the first organ to form and begins pumping blood even before valves and chambers are
formed33. Therefore, understanding key biomechanical factors that drive the events involved in
heart development are necessary to assess overall embryonic health. Organoids are thought of to
have enormous potential in studying not only organogenesis of the heart, but many organ types
within the body as well. Organoids are 3D tissues formed from the self-organization of cells to
form key features of their represented organ34. They are composed of a self-renewing stem cell
population that can differentiate into multiple cell types that exhibit cellular spatial organization
and tissue functions comparable to the corresponding organ. These stem cell-based organoid
systems, therefore can recapitulate events of early organogenesis.

1.3.2

Engineering stem cell organoids
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Organ development is often thought to be directed by surrounding biochemical signals and
biophysical cues in utero. 3D organoid technology is built upon fundamental concepts of
developmental biology, which relies on dynamic multicellular self-organization to form functional
biological tissues35. Conventional differentiation from hiPSCs and human embryonic stem cells
(hESCs) were primarily conducted under 2D cell culture systems (6-well plates) without proper
biophysical cues. Although this method is suitable for day to day hiPSC culture expansion,
differentiated tissue on standard tissue culture surfaces ultimately lack region-specific structure
and architecture seen in native tissue36. Monolayer hiPSC differentiation, therefore, does not
accurately represent the complexity of morphogenetic events that comprise organogenesis2,37,
which are governed by the synergistic interactions of biochemical and biophysical factors.

Recently, there has been progress in stem cell organoid engineering to generate a wide range of
miniature organ models resembling the brain38,39, kidney40, intestine41,42, and retina43 (Figure 2).
Organoids are engineered by controlling the size and shapes of hiPSC colonies in order to promote
self-assembly and self-organization of differentiating tissue. Organoids offer the benefit of
recapitulating tissue morphogenesis into spatially organized 3D tissue to better understand
developmental biology and for greater applicability in medication screening. Early organoid
models relied on Matrigel scaffolds to encapsulate stem cell spheroids, which self-assemble into a
functional organoid. However, since Matrigel is essentially extracellular matrix extracted from
mouse cancer cells, this presents inherent heterogeneity between batches of Matrigel and limits
the organoid reproduction consistency.

5

Efforts to promote reproducible organoid formation has, therefore, been demonstrated through
engineering fully defined synthetic materials that recapitulate natural extracellular matrix. Robust,
and highly reproducible intestinal organoids have been achieved using synthetic hydrogel
networks that not only support intestinal organoid culture, but also direct the differentiation by
carefully defining the material properties of the hydrogels44–46. The controlled parameters include
material chemistry, stiffness, and dynamics which can be fine-tuned to optimize the spatiotemporal
organoid formation. Alternative approaches to synthetic material encapsulation include controlling
the biophysical and biomechanical inputs. Microfluidic systems, for instance, has also been proven
to guide spatial organization of differentiating PSCs. Using microfluidic devices, precise signaling
can be induced to create differentiation domains of localized morphogen sources. This has been
shown particularly in modeling embryonic development, such as in germ layer patterning47, as
well as amniotic and epiblast layer formation48. Particularly, biophysical input from geometric
confinement has been employed to model in vivo gastrulation as well, where hPSCs were patterned
and differentiated to form concentric rings indicative of a specific germ layer49–51(Figure 3). These
examples

illustrate

the

necessity

of

engineering

spatiotemporally

controlled

cell

microenvironments to guide the spatial organization of stem cell organoids of specific biological
tissues.

1.4

Cardiac organoid engineering

Cardiac organoids have proven to be a challenge because of the complexity in the environmental
conditions and cell compositions of the heart. This is especially the case for the developing heart
due to the dynamic morphological and cellular changes during organogenesis. Many approaches
assemble immature cardiomyocytes (either harvested from neonatal rats or derived from PSCs)
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into constructs or combine a heterogenous mixture of cardiomyocytes and a variety of stromal
cells to create biomimetic cardiac organoids4,17,52,53(Figure 4). One of the first 3D cardiac tissue
constructs that identified the model as cardiac organoids was developed by Lee and colleagues in
2008. Using a balloon catheter and collagen-based molding, they developed a pumping organoid
chamber system that modeled a functional heart ventricle. Voges et al developed a cardiac
organoid platform that resembled fetal heart tissue with regenerative potential after
injury. Richards and colleagues developed cardiac organoids with self-organized vascular
structures that exhibited fundamental cardiac tissue functions by combining cardiomyocytes,
stromal cells, and endothelial cells (Figure 4a). Although these methods have proven applicability
for areas such as drug screening and injury modelling, they ultimately lack in their ability to study
an early developing heart because they do not incorporate the self-organization of differentiating
PSCs that is characteristic of in vivo organogenesis.

To date, very few cardiac organoids derived from the self-assembly of differentiating PSCs have
been reported in literature. One of the first models to focus on cardiac organoids based on selforganization during differentiation was the cardiac microchamber platform developed by Ma et
al.54,55 and the Healy Lab (UC Berkeley) (Figure 4b). This method was able to engineer 3D tissue
from 2D culture plates by confining hiPSC colonies into specific patterns. The cardiac
microchambers were engineered using a cell micropatterning approach that combined
photolithography, tissue culture surface modifications and selective etching of non-fouling agents
to create patterns for long term tissue confinement. Cell micropatterning methods have enabled
precise control over the cellular microenvironment (e.g., shape and size of cell colonies) that
regulates cellular morphology and functions56–58. Commercially micropatterned substrates (e.g.
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CYTOO chips etc.) are available and have been explored50, but don’t offer the same flexibility of
designing and fabricating diverse arrays of geometrical features. The novelty of cardiac organoids
generated from cell patterning is that it integrated organoid concepts with cell micropatterning
approaches to (1) promote the self-organization of 3D tissue structures to mimic early heart and
organ formation; (2) supply biophysical cues during cardiac differentiation of hiPSCs to facilitate
cellular polarity and spatial organization of cardiac tissue patterns; and, (3) reduce tissue
heterogeneity to create a systematic and experimentally reproducible in vitro cardiac organoid
model.

Using this integrative approach, Ma and colleagues found that the confined cells in various
geometries self-organized into a 3D architecture with region-specific tissue layers. Specifically,
beating cardiac tissue was primarily localized to the pattern center, whereas stromal cell types were
distributed at the edges within the perimeter of the patterns. This suggested that the biophysical
constraints experienced by cells at the pattern perimeter was a potential inducer for the cells to
follow a stromal or supportive cell type lineage. Cells at the center that were least susceptible to
the physical contact, contrastingly formed beating cardiac tissue. The resulting tissue construct is
a spatially organized tissue structure composed of supportive cells and cardiomyocytes, each
localized to specific regions in the pattern. The clinical applicability of however, has not been
explored, nor has the degree of recapitulation to native developing cardiac tissue. By answering
these questions, the cardiac organoids can contribute to the field of organoid engineering,
especially fulfilling needs in clinical applications, such as drug screening.

1.5

Scope of dissertation
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This dissertation will primarily focus on the characterization, optimization and application of
cardiac organoids that have potential to recapitulate early heart development. In addition, one
chapter is focused on analytical tools to characterize cardiac contraction, specifically for druginduced cardiotoxicity. As a whole, this dissertation encompasses tools and methods for the
advanced drug screening of cardiac physiology. The main goals of this dissertation are to: 1)
perform exploratory studies to better understand how geometric confinement influences the
formation of cardiac organoids; 2) apply the cardiac organoids as an embryotoxicity screening
platform; 3) study cell compositions of cardiac organoids to better understand biological function
of the cardiac organoids; and 4) apply sophisticated computational tools to advance the study
cardiac drug response. Chapter 2 will focus on the methodology used to generate cardiac organoids
for subsequent chapters. Chapter 3 discusses how cardiac organoid structure and functions are
governed via exploration of various geometrical patterns. Chapter 4 explores the ability of this
platform to be used as a potential application of embryotoxic drug screening, since the organoids
are hypothesized to mimic an early developing heart. A single shape and size were chosen to
generate organoids on a large scale for drug screening during differentiation, which mimics
continuous drug exposure, or medication prescription, during pregnancy. Chapter 5 discusses more
in-depth genomic characterization of the organoids using next generation sequencing analysis.
This analysis will be used to identify cell populations that comprise the cardiac organoids. Chapter
6 describes an analytical tool used to characterize drug-induced changes to cardiac contraction.
Lastly, Chapter 7 will conclude this dissertation as well as discuss the future prospective of this
work.
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Figure 1. Stem cell biology and human development. Potentials of using in vitro induced
pluripotent stem cell biology to model in vivo human cell and tissue development.
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Figure 2. Stem cell organoids exhibiting spatial-organization and features that resemble
native in vivo organs. Stem cell organoids with spatial organization and patterning have been
engineered to model numerous organs including (a) brain39, (b) kidney59, (c) intestinal42, and (d)
retinal43. All figures reproduced with copyright permissions.
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Figure 3. Stem cell organoids engineered through precise microenvironment control. (a)
Intestinal organoids generated in synthetic PEG-4MAL hydrogels46; (b) microfluidic-controlled
epiblast and amnion structures60; (c) micropatterning of human stem cells to model germ layer
formation49. All figures reproduced with copyright permissions.
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Figure 4. Cardiac organoids derived from cardiomyocytes differentiated from human
induced pluripotent stem cells. Various cardiac organoid models have been developed by
researchers. (a) vascularized cardiac organoid17; (b) self-organized cardiac organoid
microchamber54. All figures reproduced with copyright permissions.
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2. Chapter 2: Organoid generation methodology

Overview
This Chapter outlines the methodology used for generating and characterizing cardiac organoids.
The method to generate organoids is based on tissue culture surface micropatterning that confine
pluripotent stem cell colonies into a desired geometry. This confinement drives the cells to selfassemble into a 3D tissue structure during differentiation into organoids. Organoids were
characterized based on their contraction functions, tissue specifications and 3D tissue architecture.

2.1

Motivation and background of method adaptation

The Healy Lab at UC Berkeley created arrays of 3D cardiac organoids in which hiPSCs
differentiated into cardiomyocytes only in the center of each pattern (e.g., 400-µm circle patterns)
with myofibroblast-like cells forming at the perimeter54. The patterning approach consisted of
poly(ethylene glycol) (PEG)-based grafting onto standard tissue culture polystyrene and selective
shape-specific plasma etching by use of poly(dimethyl siloxane) (PDMS) stencils. PEG has been
used in numerous cell patterning techniques to supply a non-biofouling surface that rejects protein
adsorption and cell attachment, thus supplying selective regions for cell attachment and
proliferation61–63. We implemented this PEG-based patterning approach described by Ma et al.54
and Hoang et al.55 and differentiate patterned hiPSCs into cardiac organoids and characterize their
morphology, uniformity, and contractility. Unless otherwise specified, all experiments in
forthcoming chapters were based on the methodologies implemented in this chapter. A schematic
of the procedure from soft lithography to cardiac differentiation is illustrated in Figure 5a.
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2.2

Fabrication and micropatterning of tissue culture substrates

2.2.1

Fabrication of patterned silicon wafer and PDMS stencils

Patterned wafers were fabricated using standard SU8 photolithography. First, photomasks of all
different pattern shapes and sizes were designed on AutoCAD software and commercially printed
at CAD/Art Services Inc. SU8 Master wafers with desired features were fabricated with standard
photolithography following the photoresist manufacturer's instructions. To summarize the
procedure, SU8-50 photoresist (MicroChem) was spin-casted at a specified speed to attain features
100 μm in height. SU8 is a negative photoresist that cures upon exposure to UV light, and thus
cannot be washed away with developer solution. The SU8 casted wafer was quickly exposed to
high intensity UV light with the photomask on top to crosslink the features designed on the masks.
The masks retain transparent features that allow UV penetration in the desired shapes and sizes.
The wafers were then baked post-UV exposure and soaked in a developer solution to remove
uncured photoresist. This standard process essentially creates a mold with raised features that will
be used for fabrication of PDMS stencils. Furthermore, a silane solution (1H,1H,2H,2HPerfluorooctyltriethoxysilane; Sigma Aldrich) was vacuum deposited onto the wafers to increase
the hydrophobicity of the wafer for easy removal of the stencils.

Stencils were fabricated using standard soft lithography techniques. PDMS pre-polymer (Sylgard
184) was mixed at a 10:1 wt/wt ratio of elastomer base to curing agent and the mixture is degassed
under vacuum. A small amount (about 1 mL) of PDMS pre-polymer was poured onto each wafer
and pressed down with a square piece of transparency plastic, cut to the size of the wafer (Figure
5b). The transparencies are pressed down further by placement of glass slides on top and then the
wafer-PDMS-transparency-glass construct is then clamped with large binder clips (Figure 5c).
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This allows the PDMS to spread throughout the array of patterns and create open holes
corresponding to the features on the wafer. The constructs were placed in a 60 ºC oven overnight,
and the cured stencils were peeled and cut to fit into a 35 mm tissue culture well (Figure 5d).

2.2.2

PEG-based surface patterning

To pattern tissue culture polystyrene, a thin solution of PEG is grafted and selectively etched using
the PDMS stencils and oxygen plasma. The PEG solution is prepared by combining and vortexing
150 mg PEG 1000 (Polysciences), 1.8 mL PEG (400) diacrylate (PEGDA) (Polysciences), 15.55
mL isopropanol and 0.45 mL MilliQ water. 760 µL of the solution was grafted onto individual
wells of a 6-well plate that was pretreated for three minutes with oxygen plasma. The grafted plates
were exposed to high-intensity UV light to polymerize the PEG at the surface and leaving behind
residual polymer. The residual polymer was then washed away with MilliQ water to obtain an
optically clear surface. Next, the PDMS stencil was placed on top of the PEG-grafted surfaces,
which leaves selectively exposed regions of PEG to be etched with oxygen plasma treatment
(Figure 5e). The etching removes the PEG from these regions exposed by the stencils and creates
biofouling patterns for cell attachment. The patterned surfaces with stencils still adhered were
sterilized and coated with hESC-qualified Geltrex Matrix (ThermoFisher) for hiPSC attachment.
To sterilize, each well was filled with 70% ethanol and allowed to sit for 1 hour under a biosafety
cabinet. The remaining ethanol was aspirated and washed with phosphate buffered saline (PBS).
Thin-gelling hESC-qualified basement membrane matrix (Geltrex) was added to each well,
completing the surface patterning and preparation for cell seeding.

2.3

Patterning and cardiac differentiation of hiPSCs
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2.3.1

Human iPSC culture maintenance and seeding

Human iPSCs derived from healthy adults were cultured and expanded using standard pluripotent
stem cell culture techniques. Our lab protocol specifically maintains hiPSCs on Geltrex coated
plates in Essential 8 (E8) medium and passaging with Accutase dissociation reagent. E8 medium
was changed daily to maintain cell health and viability. The cells were considered ready for
passaging and seeding at approximately 80% confluence. The patterned and coated plates were
incubated at 37ºC for 1 hour prior to cell seeding to activate proteins within the Geltrex matrix.
The confluent hiPSCs were washed with PBS and incubated with Accutase dissociation reagent
for 4 minutes until the cells were visibly detached. The cells were centrifuged, resuspended in E8
medium supplemented with 10 µM Y27632 and seeded onto the patterned tissue culture plates at
a seeding density of 0.4E6-0.7E6 cells. The range accounts for the different sizes that are to be
explored in this aim, as well as the variable growth kinetics of each cell line. After 24 hours, the
stencils inside the wells were carefully removed with sterile tweezers, leaving behind only the cells
that have attached within the patterns. In addition, E8 media was changed to remove the Y27632.
In most cases, with daily feeding of cells, hiPSC colonies were able to proliferate and fill patterns
to confluency around 72 hours after seeding to begin differentiation.

2.3.2

Patterned hiPSCs maintain pluripotency

When the patterned hiPSCs reached confluency, we performed simple quality control experiments
to ensure optimal differentiation capacity of the hiPSCs. Specifically, we performed
immunofluorescence characterization to test for expression of pluripotent transcription factors and
surface markers. The confluent patterns showed positive expressions of OCT4, SOX2, NANOG,
E-cadherin, and SSEA4 that were distributed across all cells (Figure 6). This indicated that the
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patterned hiPSCs maintained their pluripotent potential and do not undergo uncontrolled
spontaneous differentiation.

2.3.3

Differentiation of patterned hiPSCs into cardiac organoids

Cardiac differentiation was initiated approximately three days after initial seeding when the cells
reached confluency in the patterns (Figure 7). Differentiation was performed via small molecule
modulation of the Wnt/Beta date in pathway64 (Figure 8). Small molecule stocks were dissolved
in sterile DMSO and diluted to their final concentrations in RPMI 1640 medium supplemented
with B27 minus insulin (RPMI1640/B27-I). First, to initiate differentiation, the culture medium
was exchanged with 10 uM GSK3 inhibitor CHIR99021 (Day 0) for 24 hours and then exchanged
with fresh RPMI1640/B27-I on Day 1. On Day 2, the medium was exchanged with 5 uM of WNT
pathway inhibitor IWP4 (Day 2) for 48 hours. On Day 4, the IWP4 was removed and replaced
with fresh RPMI1640/B27-I. On Day 6 onward, the medium was changed to RPMI1640
supplemented with B27 complete supplement (RPMI1640/B27+C) every two days until
termination around Day 20. The patterned cells change morphology throughout differentiation,
beginning as a 2D monolayer of hiPSCs self-assembling into a tissue structure that exhibits
spontaneous contraction at around Day 10 of the differentiation timeline.

2.4

Cardiac organoid function and 3-dimensional morphology

2.4.1

Characterization of cardiac organoid contraction function

The contraction function of cardiac organoids was characterized at or around Day 20 of
differentiation (Figure 9a). The day of termination was determined based on visual examination
of the overall quality of the cardiac organoids over time, as many cells began to die if cultured for
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too long, especially the cardiomyocytes. Before termination, contraction videos were recorded at
a minimum of 50 frames per second for video-based contraction analysis. Organoids were imaged
in an onstage microscope incubator (OkoLab Stage Top Incubator, UNO-T-H-CO2) at 37 ˚C and
5% CO2 to maintain standard physiological conditions on a Nikon Ti-E inverted microscope with
Andor Zyla 4.2+ digital CMOS camera. The videos were exported as single image sequences and
analyzed using an open source Motion Tracking Matlab script developed by Huesch et al. The
software implements block matching to compute motion vectors representing the motion velocities
created by the contractile behaviors of the tissue. Furthermore, the motion vectors can be
reconstructed into contraction motion waveforms that are representative of the muscle
contraction/relaxation cycles of the tissues. Direct parameters that were exported were the
contraction and relaxation velocities, beat rate, and beat duration.

2.4.2

Characterization of cardiac organoid morphology

Immunofluorescence staining was the primary method for characterization of cell type and tissue
morphology, allowing analysis in both 2D and 3D. After video recording, samples were sacrificed
and fixed with 4% (vol/vol) paraformaldehyde (PFA) for 10 minutes. After PFA treatment,
samples were washed and permeabilized with 0.2% (vol/vol) Triton X-100, blocked with 2%
(wt/vol) bovine serum albumin (BSA) and incubated with the appropriate dilution of primary
antibodies for 1 hour at room temperature. After incubation, the primary antibody was removed
and washed with PBS. Secondary fluorescent antibodies were then incubated in the dark for 2
hours at appropriate dilutions and nuclei were tagged with 300 nM DAPI. The antibodies used
consisted of at least three markers of terminal cardiomyocytes and at least three markers of smooth
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muscle (Table 1). Confocal microscopy (Zeiss U880) was used to capture z-stacks (8 um spacing
between slices) of the organoids for height measurements and 3D reconstruction.

The cardiac organoids were assessed based on three parameters that characterize the overall
cardiac tissue distribution and 3D morphology (Figure 9b, c). All images were imported into
ImageJ for image reconstruction and analysis. The Area Ratio was measured by using the circular
or elliptical tool to approximate the area of fluorescence of tissue staining positive for cardiac
tissue and normalizing this area relative to the area of the entire pattern. The Height was measured
by locating the top and bottom of the organoids using confocal microscopy. Lastly, the FWHM
was determined by measuring the tissue diameter at half of the organoid height.

2.5

Cardiac organoid gene expression analysis

On Day 20 of differentiation, cardiac organoids were sacrificed for RT-qPCR analysis. RNA was
extracted using the RNeasy Mini Kit (Qiagen) and stored in -80 ˚C until needed. The RNA was
then converted to cDNA using the Superscript IV First Strand Synthesis kit (Thermofisher). Genes
of interest include cardiomyocyte-specific genes and stromal cell genes, plus TaqMan array of
human factors for cardiogenesis (Thermofisher) (Table 2). PCR plates were prepared according to
standard protocol provided by Thermofisher and then run using the QuantStudio 3 Real-Time PCR
System. All data was normalized to the respective housekeeping genes that were run in parallel
with the rest of the gene assays.
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2.6

Statistical analyses

All box plots show the minimum, maximum, median, and 25th and 75th percentiles. Unless
otherwise stated, statistical analysis was performed based on analysis of variance (ANOVA) with
Tukey’s multiple comparison test.
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Figure 5. Schematic of procedure and process of PDMS stencil fabrication
(a) Schematic outlining key steps of the entire procedure. (b) SU8 master with a small amount of
PDMS prepolymer. (c) Completed assembly of the patterned SU8 master-PDMS-transparencyglass slide construct. (d) Thin film of PDMS removed from the assembly after curing and then
placed on top of the optically clear PEG grafted surface (e). Figure reproduced from Hoang et al.
2018 Nature Protocols55.
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Figure 6. Quality control of patterned hiPSC pluripotency. The micropatterned hiPSC colonies
maintained the expression of pluripotency markers of (from left to right) OCT4, NANOG, Ecadherin, SOX2, and SSEA4. Scale bar, 200 µm.
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Figure 7. Confluent micropatterned hiPSC colonies. Bright-field microscopy images of arrays
of micropatterned hiPSCs with different sizes and shapes. Scale bar, 400 µm. Clockwise: 200 µm
circles, 400 µm circles, triangles, and 600 µm circles.
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Figure 8. Cardiac differentiation timeline to generate cardiac organoids. Patterned cell
morphology changes from 2D monolayer of cells (D0) into 3D tissue (D6 onward) throughout
differentiation; scale bars 600 µm.
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a

b

c

Figure 9. Cardiac organoid function and structure characterization. (a) Motion tracking
analysis based on vector computation of pixel movement generates contraction velocity
waveforms representing beat cycles of the cardiac organoids. (b) Immunofluorescence staining
used to compute the Area Ratio, which is the area of cardiac tissue (cTnT) coverage relative to the
area of the entire pattern. (c) Confocal imaging was used to capture z-stacks of the tissues, which
were reconstructed for 3D morphological scoring of the height and full-width at half-maximum
(FWHM). Scale bars 200 µm.
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Table 1. List of primary and secondary antibodies used for immunofluorescent staining and
imaging
Primary antibodies (species)

Vendor

Catalog No.

Dilution

Cardiac troponin T (mouse)

Thermo Fisher Scientific

MS295P

1:200

Sarcomeric α-actinin (mouse)

Sigma-Aldrich

A7811

1:300

Myosin heavy chain (mouse)

Abcam

Ab97715

1:200

Cardiac troponin I (rabbit)

Abcam

Ab47003

1:200

Vimentin (mouse)

Thermo Fisher Scientific

MA5-11883

1:100

α-SM22 (rabbit)

Abcam

Ab14106

1:300

Calponin (rabbit)

Abcam

Ab46794

1:200

α-Smooth muscle actin (rabbit)

Abcam

Ab5694

1:100

OCT4 (rabbit)

Abcam

Ab18976

1:200

NANOG (mouse)

Thermo Fisher Scientific

MA1-017

1:100

SSEA4 (mouse)

Stem Cell Technologies

60062

1:200

SOX2 (rabbit)

Thermo Fisher Scientific

PA1-094

1:100

E-cadherin (mouse)

Abcam

Ab1416

1:200

Alexa Fluor 488 goat antimouse IgG

Thermo Fisher Scientific

A-11029

1:200

Alexa Fluor 546 goat antimouse

Thermo Fisher Scientific

A11003

1:200

Alexa Fluor 488 goat antirabbit IgG

Thermo Fisher Scientific

A11008

1:200

Alexa Fluor 546 goat antirabbit

Thermo Fisher Scientific

A11010

1:200

Secondary Antibodies
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Table 2. TaqMan arrays used for gene expression analyses
Taqman Assay ID
Hs00155658_m1
Hs00609603_m1
Hs00181051_m1
Hs00153179_m1
Hs00394718_m1
Hs00205566_m1
Hs00154192_m1
Hs00370078_m1
Hs00233476_m1
Hs01034913_g1
Hs00176144_m1
Hs00176148_m1
Hs01026536_m1
Hs00372959_m1
Hs00154374_m1
Hs00270923_s1
Hs00193796_m1
Hs00175141_m1
Hs00959434_m1
Hs00355045_m1
Hs00183740_m1
Hs00737028_m1
Hs00153451_m1
Hs00231667_m1
Hs00605457_m1
Hs00608098_m1
Hs00231092_m1
Hs00242501_m1
Hs00266645_m1
Hs00268943_s1
Hs00273077_s1
Hs00184043_m1
Hs00201853_m1
Hs00361869_g1
Hs00171574_m1
Hs00275833_s1
Hs00259040_s1
Hs00171403_m1
Hs01053355_m1
Hs01064686_m1
Hs00197803_m1
Hs00387073_m1
Hs00255603_m1
Hs01564092_m1
Hs00275656_m1
Hs99999908_m1
Hs00231848_m1
Hs00232769_m1
Hs00167041_m1
Hs01001602_m1

Gene/Array Name
ACVR2A
ACVR2B
APC
ATF2
AXIN1
BMP10
BMP2
BMP4
BMP7
BMPR1A
BMPR1B
BMPR2
CCNE1
CCNE2
CDC6
CEBPB
CER1
CHUK
CNN1
CTNNB1
DKK1
DVL1
E2F1
E2F2
E2F3
E2F4
E2F5
E2F6
FGF2
FZD1
FZD10
FZD3
FZD4
FZD5
FZD6
FZD7
FZD8
GATA4
GNAI1
GNAI2
GNAI3
GNAQ
GNAS
GNB3
GSK3B
GUSB
HAND1
HAND2
HNF1A
HNF1B

Taqman Assay ID
Hs00177373_m1
Hs00176247_m1
Hs00231149_m1
Hs01101425_m1
Hs01110632_m1
Hs00293096_m1
Hs00166405_m1
Hs04187281_m1
Hs00231763_m1
Hs00415443_m1
Hs00276431_m1
Hs00383231_m1
Hs00173590_m1
Hs01065279_m1
Hs00176973_m1
Hs00176998_m1
Hs01090047_m1
Hs00178455_m1
Hs00177010_m1
Hs00702254_s1
Hs00989970_m1
Hs00177051_m1
Hs01078066_m1
Hs00195432_m1
Hs00183425_m1
Hs00929647_m1
Hs00195437_m1
Hs00195441_m1
Hs01038777_g1
Hs01385457_m1
Hs00911929_m1
Hs00396596_m1
Hs01052563_m1
Hs00413032_m1
Hs01009038_m1
Hs02339499_g1
Hs00998133_m1
Hs00234244_m1
Hs01086000_m1
Hs00610318_m1
Hs00234253_m1
Hs00165957_m1
Hs00943911_m1
Hs00958111_m1
Hs00182986_m1
Hs00263977_m1
Hs00230534_m1
Hs00610126_m1
Hs01103751_m1

Gene/Array Name
MAP3K7
MAPK14
MEF2C
MYH6
MYH7
MYH7B
MYL2
MYL4
NKX2-5
NODAL
NOX4
NPPA
NPPB
PECAM1
PRKCA
PRKCB
PRKCD
PRKCE
PRKCG
PRKCI
PRKCQ
PRKCZ
RB1
SMAD1
SMAD2
SMAD4
SMAD5
SMAD9
TAGLN
TBX18
TBX2
TBX20
TBX5
TCF3
TCF7L2
TDGF1
TGFB1
TGFB2
TGFB3
TGFBR1
TGFBR2
TNNI3
TNNT2
VIM
WNT11
WNT3A
WNT8A
WNT8B
WT1
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3. Chapter 3: Geometric confinement on cardiac organoid
development

Overview
The goal of this chapter is to assess different confinement conditions and determine which
geometries would yield optimal and efficient generation of cardiac organoids. This chapter
describes the various shapes used to perform this particular study, where our goal was to assess
how the geometry directs the differentiation of cardiac organoids. Previously, cardiac organoids
were primarily generated in circular shapes, which demonstrated that the biophysical stresses from
the constraint produced supportive cell types that were localized along the pattern perimeter.
Therefore, we hypothesized that shapes with angular geometries can provide greater biophysical
stress and will influence the cell specification trajectories of the cardiac organoids. The influence
of the polygonal geometries was first assessed by studying the formation of organoids in circular,
triangular and square shapes. Then, we assessed the influence of size on the differentiation of the
organoids. From these data collected, we evaluated how geometry and size affects the 3D tissue
morphology and cardiac functions of cardiac organoids.

3.1

Background and rationale

Cell patterning methods to create specific geometric conditions have been used extensively to
govern the morphogenetic events of 3D tissue formation54,65–69. These studies have shown that
stem cell differentiation can be driven by pattern geometry, where a specific shape can favor
differentiation into a particular cell type. In addition, studies modelling mammalian development
have also demonstrated the spatial differences of cell proliferation and differentiation between
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pattern center and perimeter due to the mechanical stress presented by geometric confinement50,70.
These studies suggest that tissue formation and cell specification is highly governed by biophysical
factors as well as structure–function relationships that drive developmental processes. Thus,
models of 3D tissue morphogenesis should consider tissue geometry and mechanical stress as
inductive cues for spatial tissue organization during differentiation.

This chapter discusses an exploratory study design where various shapes were used to generate
cardiac organoids. These shapes include circular, triangular, and square geometries scaled to the
same area as a 400 µm diameter circle. In addition, we assessed shape size by generating cardiac
organoids in circles ranging from 200 um - 1000 um in diameter. Photomasks for the respective
patterns were designed using AUTOCAD and fabricated as per procedure described in Chapter 2.

3.2

Shape confinement on cardiac organoid development, function, and morphology

3.2.1

Cardiac organoid structure

Cardiac organoids were generated using the methodology described in the previous chapter. First,
using circular organoids, we verified the cardiac specification through immunofluorescent staining
at different differentiation stages. There was positive expression of mesoderm marker BRA on
Day 1, and cardiac progenitor markers NKX2.5 and GATA4 on Day 10, indicating a transition
from pluripotency to the appropriate cardiac specification (Figure 10a). This approach generated
robust contracting cardiac organoid arrays of 50-100 organoids within 20 days. We found that
cardiomyocytes were primarily differentiated on the center top of the organoids, demonstrated by
multiple cardiac-specific markers (Figure 10b): cardiac troponin T, myosin heavy chain β,
sarcomeric α-actinin, and cardiac troponin I, while smooth muscle-like stromal cells distributed
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along the pattern perimeter, indicated by positive expression of α-smooth muscle actin, calponin,
α-SM22, and vimentin (Figure 10b).

3.2.2

Shape influence on organoid contractile functions and structure

The study design consisted of comparing organoid generation from three pattern shapes (circle,
square and triangle) with the same scaled area (Figure 11a). We found that cardiac organoids from
circular patterns exhibited significantly higher contraction velocity, lower average beat rate, and
longer beat duration (Figure 11b-d). Circles also produced the organoids with larger area ratios
than squares and triangles (Figure 11e). For 3D tissue morphology, the cardiac organoids from
triangle and square patterns were consistently lower in height and FWHM than the circles. Thus,
the polygonal geometries inhibited the capacity of the cells to form organoids with comparable
structural integrity to the circular organoids (Figure 11f, g). These observations illustrate that the
development of cardiac organoids is affected by the pattern shape, in which the angular geometry,
like triangles, presents high physical constraint to the cells.

We hypothesized that polygonal constraint promotes a higher degree of differentiation into the
stromal cell types, rather than cardiomyocytes. We plotted the structure-function correlations and
observed a decline in the contraction rate that corresponded to the increasing area ratios (Figure
11h). This demonstrated an inversely proportional relationship between the cardiac tissue size and
the contraction rate. The decline in contraction rate can be attributed to higher contraction
velocities exhibited by the circular organoids, since larger muscle tissues and robust contraction
results in the tissues taking longer to contract. From the structure-structure correlations (Figure
11i), we observed that triangular organoids were clustered with smaller values of height and

31

FWHM, while circular organoids were generally larger in these aspects, which correlates to
increased tissue volume. Overall, the circular pattern geometry promoted more robust formation
of cardiac organoids with large size and high contractile functions.

3.3

Size confinement on cardiac organoid development, function, and morphology

3.3.1

Cardiac organoid function and structure is limited by size

To examine the effects of pattern size on cardiac organoid development, we generated organoids
in circular patterns ranging 200 – 1000 µm in diameter (Figure 12a). The 200 μm patterns did not
reliably produce the organoids consistently or efficiently. The percentage of patterned hiPSC
colonies of 200 μm circles that were able to successfully form organoids was very low (~ 20%),
in comparison to all other sizes where the efficiency was approximately 80%. We found no
significant differences on beat rate (Figure 12b), contraction velocities (Figure 12c) and beat
duration (Figure 12d) among different pattern sizes, with the exception of the 200 μm organoids
due to the inconsistent differentiation capacity of this size. For the remaining sizes, this indicated
that size did not significantly affect the contractile functions of cardiac organoids.

In contrast, the pattern size had apparent effects on morphology and architecture of the organoids.
The circles with 200 µm diameter produced the cardiac organoids with the largest area ratio of
cardiac muscles amongst all the circle sizes, albeit with the largest variability as well (Figure 12e).
Regarding the circles with large sizes (800 µm and 1000 µm), these patterns produced the
organoids with a greater area ratio (> 0.60) in comparison to the 400 µm and 600 µm circles (~
0.50). Despite the larger cardiac muscle distribution of the larger circles, the organoid height was
much lower on these larger circles compared to 400 µm and 600 µm circles (Figure 12f).
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Additionally, the FWHM steadily increased with increasing pattern size, peaked at 600 μm
patterns, and decreased with larger sized circles (Figure 12g), indicating the greatest 3D
architecture of the cardiac organoids at 600 μm.

The structure-function relationships for the cardiac organoids showed clusters of organoids with
pattern size larger than 400 µm, indicating the consistency in the organoid production. Instead,
200-µm organoids showed a much more scattered distribution of structure-function relationship,
corresponding to faster beat rate and larger size. However, independent of the size increase from
400 µm to 1000 µm in diameter, the area ratios of these cardiac organoids remained consistent,
which in turn produced organoids with comparable contractile function (Figure 12h). Regarding
the 3D architecture of the cardiac organoids, a clear cluster separation of 600-µm organoids from
other pattern sizes showed largest values of height and FWHM (Figure 12i). These results suggest
that larger patterns do not further promote the cell assembly into a 3D structure with a significant
reduction in 3-dimensionality of the cardiac organoids. It is inferred that as the pattern size
increases further, the tissue formation begins to resemble that of 2D cardiac differentiation from
hiPSCs. Overall, the pattern sizes have prominent effects on the structure and morphology of
cardiac organoids, but less on the contractile functions.

3.3.2

Organoid size influences cardiogenic gene expression

To study how geometric confinement affected the cell fate choice of cardiac organoids, we profiled
the gene expression of organoids with 200 μm, 600 μm, and 1000 μm diameter patterns (Figure
13a). We found up-regulation of cardiomyocyte-specific markers (MYH7, MYH7B, MYL2,
Nkx2.5, MYL4, and TNNI3) and down-regulation of stromal cell markers (TAGLN and CNN1)
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in large pattern sizes (600 µm and 1000 µm diameter circles) (Figure 13b). This data supported
our previous contractile, structural, and morphological analyses, where cardiac differentiation and
contractile functions were more robust in the organoids of larger pattern sizes. We also found that
PRKC-related genes were highly expressed in the 200 µm organoids, attributing to the smooth
muscle phenotype promoted by the geometric confinement71–73 (Figure 13c). In addition, BMP10,
FGF2, FZD10, TBX18, and WT1 were also upregulated in 200 μm organoids, suggesting that
small pattern size promoted the differentiation into possibly epicardial or epithelial stromal
progenitor cells74,75. In contrast, genes of BMP7, HNF1B, NPPA, and SMAD9 were upregulated
in 1000 µm patterns, which possibly indicated a greater degree of cardiac growth and
morphogenesis, as these genes are involved in the pathways critical to the later stages of cardiac
chamber formation76–78, and dysregulations in these pathways have resulted in cardiac defects79,80.

3.4

Conclusions and discussion

In this study, we were able to generate the cardiac organoids from various pattern sizes and shapes
and found prominent impact from the geometric confinement on organoid morphology and
functions. The high compactness that the cells may be experiencing within the geometries of small
size or polygonal corners resulted in a higher degree of differentiation into stromal cell population,
other than cardiac muscles, which in turn affected the tissue morphology and contractile functions.
Research in cardiac tissue engineering has exploited the co-dependency of tissue structure and
function, such that the structure of engineered tissues would have a profound effect on the capacity
of the tissue to perform their desired functions6,26. Such structure-function correlation of cardiac
tissues has been studied as early as the first several demonstrations of growing cardiomyocytes in
defined anisotropic geometries81. The combination of tissue engineering and organoid technology
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provides the versatility and capability to generate the cardiac organoids of desired architectures
with enhanced contractile functions, which can be useful in the design principles for organoid
engineering.
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Figure 10. Differentiation from pluripotency into cardiac organoids. (a) 24h after CHIR
treatment, patterned hiPSCs express mesodermal marker brachyury. (d) On Day 8 of
differentiation, cardiac organoids express ISL1, followed by (d) NKX2.5 and GATA4 on Day 10,
indicative of early cardiac progenitor cells; scale bars 200 µm. (b – top row) The spatial-organized
cardiac organoids showed cardiac muscle on the top center with cardiomyocyte-specific proteins
(cardiac troponin T (cTnT), β myosin heavy chain (MHC-β) sarcomeric α-actinin and cardiac
troponin I (cTnI)) and smooth muscle-like cells on the perimeter of the organoids with stromal cell
markers (smooth muscle actin (α-SMA), calponin, transgelin (α-SM22) and vimentin). Scale bar,
200 µm. (b – bottom row) confocal microscopy images of cardiomyocytes on the cardiac
organoids. Scale bar, 50 µm.
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Figure 11. Geometry effect on cardiac organoid function and structure. (a) Confocal
reconstructions of cardiac organoids generated in circular, triangular, and square shapes; scale bars
200 µm. From comparison of contraction function of cardiac organoids as influenced by shape
geometry, (b) triangular and square organoids exhibited significantly decreased contraction
velocity (n ≥ 10, *p = 0.0024), but (c) significantly faster beat rate (n ≥ 9, *p ≤ 0.0001) with (d)
longer beat duration (n ≥ 9, *p ≤ 0.0001) relative to circular organoids. Structural 3D
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morphological scoring of cardiac organoids showed that circle shapes produced organoids that
were significantly larger in area ratio (n ≥ 16, *p ≤ 0.0001) than triangle and square organoids.
Only triangle organoids produced significantly decreased tissue height (n ≥ 9, *p = 0.0013) and
both triangular and square organoids had significantly smaller FWHM (n ≥ 9, *p ≤ 0.0001). (h)
Structure-function correlation plot illustrating the effect of structure on cardiac contraction. (i)
Structure-structure correlation plot illustrating shape influence on 3D architecture. In all panels,
box plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical
analysis was performed based on analysis of variance (ANOVA) with Tukey’s multiple
comparison test.
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Figure 12. Pattern size effects on cardiac organoid characteristics. (a) Cardiac organoids
generated from the circular patterns with different sizes (200 µm – 1000 µm in diameter) showed
spatial-organization of cardiomyocytes and stromal cells and 3D dome-shape in the X-Z plane.
Scale bar, 200 µm. Contractile motion analysis showed no significant differences in contraction
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velocity amongst the cardiac organoids generated from different pattern sizes, but 200-µm patterns
generated the organoids with significant differences in beat rate and beat duration comparing to
the other pattern sizes (n = 10, *p < 0.0001 for beat rate; *p < 0.0001 for beat duration). The area
ratio between cardiomyocyte staining and entire pattern size showed significant larger coverage
but higher variation in cardiac muscle differentiation on the cardiac organoids generated from the
patterns with 200 µm, 800 µm and 1000 µm diameter (n = 9, *p ≤ 0.0001 between 200 µm and
400/600 µm; *p ≤ 0.0001 between 400/600 and 800/1000 µm). The cardiac organoids generated
from 600-µm diameter circles exhibited better 3D morphology with largest values in (f) height (n
= 8, *p = 0.0126 between 200 µm and 600 µm; *p = 0.0126 between 600 and 800/1000 µm) and
(g) FWHM (n = 8, *p ≤ 0.0001 between 600 µm and 200/400 µm; *p ≤ 0.0001 between 600 and
800/1000 µm). (h) Structure-function correlation plot for the cardiac organoid generated from
different pattern sizes showed close clustering of the circular patterns of 400 – 1000 µm diameters,
except for 200 µm diameter. (i) Structure-structure correlation plot showed that 600-µm diameter
circular pattern consistently produced the cardiac organoids with the largest 3D structure. (j) Gene
expression analysis showed that larger pattern sizes (600 µm and 1000 µm diameter circles) were
associated with high expression of cardiac muscle-related genes, while small pattern (200 µm
diameter circle) was associated with high expression of stromal-related genes. In all panels, box
plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical analysis
was performed based on analysis of variance (ANOVA) with Tukey’s multiple comparison test.
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Figure 13. Gene expression patterns directed by pattern size. (a) Gene expression heatmap of
104 genes assayed the cardiac organoids generated from 200 µm, 600 µm, and 1000 µm – diameter
circular patterns. (b) Gene expression of cardiac-specific and smooth muscle/stromal genes
normalized to the expression of GAPDH housekeeping gene. (c) The signaling-related genes
showed highly differentiated expression.
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4. Chapter 4: Cardiac organoids as an embryotoxicity screening
platform

Overview
This Chapter discusses the use of cardiac organoids as a drug screening platform, specifically for
drug toxicity during fetal development. Since the organoids are derived from pluripotency and
represent self-organizing cells during differentiation, it is assumed that they better mimic immature
cardiac tissue that possesses early developmental phenotypes. Using this model, nine drugs were
screened, and the toxicity was measured via assessment of inhibition to the contraction functions
and tissue structures. The cardiac organoid model was also compared to danio rerio zebrafish
embryos as an in vivo model of heart development. By cross comparison of both models, this
Chapter concludes with advantages and limitations of both methods regarding embryotoxicity
screening.

4.1

Background and rationale

At the end of 2014, the FDA removed the pregnancy category system from drug product labeling
since it did not accurately communicate a medications’ degree of fetal risk. Certain medications
administered during pregnancy have been attributed to cause adverse effects on fetal development.
However, many drugs are still not well understood regarding their effects on human organogenesis.
As a result, pharmaceuticals are often completely avoided during pregnancy due to possible, but
uncertain risks. This leads to essential medications, like antidepressants and chemotherapeutics, to
be withdrawn, despite the benefits to the mothers’ health, because the risks on fetal development
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are unclear. Regardless, nearly 40% of pregnant women in the US receive a drug from category C
each year, while as many as 280,000 pregnant women are exposed to drugs (category D or X) with
clear evidence of potential fetal risk. As such, about 2 to 3% of all birth defects result from drugs
that were taken to treat a disorder or symptom82. The most commonly reported birth defects are
heart related, and the potential for generating cardiac defects is of utmost concern when
determining fetal drug safety. During embryogenesis, the heart is the earliest functional organ to
form, exhibiting contraction and pumping blood as early as Day 22 of human development.
Because of this naturally occurring milestone event in human development, it is acceptable to
hypothesize that disruptions in heart development bears the possibility of resulting in gross fetal
defects, allowing us to predict overall embryonic health. Thus, there is a need to establish a basis
that recapitulates human myocardium development for effective recapitulation of heart
development.

Numerous vertebrate model organisms have been utilized to screen for teratogenicity, including
whole rodent83, frog84, and zebrafish85,86 embryonic tests. However, predicting teratology using
whole embryo screening has serious drawbacks, including differences in pharmacokinetics and
metabolic pathways between species83. To overcome these challenges, researchers have developed
sophisticated in vitro alternatives to reduce the complexity, cost and time associated with whole
embryo screening to more efficiently screen for developmental toxicity. The mouse embryonic
stem cell test (mEST)87, an in vitro developmental toxicity assay using cardiac differentiation, has
been adopted by a number of pharmaceutical companies as a tool to assess the embryotoxicity of
drug candidates at the early stages of drug development88. More recently, hiPSCs have been
proposed to replace the mEST for better teratogenic predictions by overcoming the species barrier
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that has always posed limitations in traditional drug screening89. Advances in hiPSC technology
have demonstrated potential solutions because not only do they have the capability to differentiate
into almost any cell type, these cells can be patient specific, which opens opportunities for
personalized medicine and more precise diagnostics. Additionally, hiPSC-derived tissues exhibit
characteristics of early developmental lineage. For example, pluripotent stem cell derived
cardiomyocytes are smaller in size, develop less mitochondria, and do not display aligned
sarcomeric structures, which are all indications of early immature cell phenotypes30. Because of
this unique characteristic, hiPSC-derived tissue has the potential to serve as a versatile tool to study
and recapitulate events of tissue development.

4.2

Experimental procedure to mimic fetal drug exposure

From the results illustrated in Chapter 3, the optimal shape to produce cardiac organoids were
circles of 600 um diameter. Organoids of this shape and size had consistent and robust contraction
physiology, as well as the largest 3D architectures and were, therefore, determined to be the most
reliable for larger scale drug screening studies. The cardiac differentiation protocol was modified
to include the continuous supplement of drugs beginning at Day 1, 24 hours after treatment of
GSK3 inhibitor CHIR99021, of the differentiation timeline (Figure 14a) and supplemented for the
entirety of differentiation until termination for analysis. Drug supplementation during this period
applies to all differentiation events specific to cardiac differentiation and also mimics continuous
drug exposure during pregnancy. Concentrated drug compound stock solutions were dissolved in
either DMSO or MilliQ water depending on their solubility. Stocks were further diluted into
working concentrations in the corresponding culture mediums. In total, nine drug compounds were
tested and analyzed at three concentrations each, along with a vehicle control. The drugs used are
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listed in Table 3 and range in safety from Categories A to X, as determined by the previously
established FDA pregnancy category system. Drug concentrations were arbitrary, but chosen
primarily based on solubility in culture medium, as well as approximated around peak plasma
concentrations. Concentrations were increased by a factor of 10 for each incremental dosage in
order to assess extreme dosages to evaluate potential toxicity to the organoid development.

4.3

Cardiac organoids as an in vitro assay of developmental toxicity

4.3.1

Sensitivity of cardiac organoid toxicity response to well-established safe and toxic drugs

Drug treatment concentrations were chosen based on peak plasma concentrations reported by
public databases provided by the FDA (https://www.accessdata.fda.gov/scripts/cder/daf/), or
through tested concentrations reported in literature. First, we compared two drugs between
category A and category X, both as positive and negative controls (Figure 14 b, c). Doxylamine
succinate is clinically prescribed as a sleeping aid and is widely accepted drug to safely prescribe
during pregnancy, as it was established as a Category A medication. A typical 25mg oral dosage
results in mean peak plasma concentration of ~125 ng/mL (approx. 0.5 µM)90. Thalidomide is
clinically prescribed as an anti-inflammatory as well as treatment for myeloma and has a reported
peak plasma concentration approximately ranging from 0.62 – 2.82 µg/mL (approx. 2.4 – 10 µM)
in humans91. Thalidomide is widely accepted as a Category X drug, because of the well-known
birth defects that were first discovered in the 1950s that tied back to the administration of this drug
to treat morning sickness in pregnant women.

We found that doxylamine succinate (Category A) at all concentrations tested, which were above
the normal peak plasma concentrations, had no negative effect to cardiac tissue distribution (Figure
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14d). In contrast, thalidomide (Category X) had produced the abnormal cardiac organoids with
less cardiac tissue coverage relative to the untreated controls (Figure 14e). Although doxylamine
succinate showed no significant effect on the cardiac differentiation, this drug had a prominent
effect on the cardiac contractile functions with lower contraction velocity and slower beat rate
(Figure 14f, h). We hypothesize that these occurrences are a result of the inherent therapeutic
properties of this drug, as doxylamine succinate is prescribed as a sleeping aid, which has relaxant
effects and also prescribed as an analgesic to reduce muscle tension92. In contrast, there was no
significant effect from thalidomide on the contraction velocity, though high concentration of drug
dosage led to high variability in the beat rate (Figure 14g, i). More importantly, high concentration
of thalidomide (100 µM) impaired the 3D morphology of the cardiac organoids with significantly
lower height and FWHM relative to the controls and in comparison to minimal structural
impairment seen with doxylamine succinate treatment (Figure 14j-m). This indicated that exposure
of this well-known teratogen resulted in severe impairment to hiPSC differentiation and
organization into 3D cardiac tissues, which confirmed that this organoid model was sensitive to
the morphological defects as a result of drug exposure.

4.3.2

Cardiac organoid sensitivity to Category B - Amoxicillin

Next, we tested the cardiac developmental toxicity of the drugs from the other pregnancy
categories. Amoxicillin (category B) (Figure 15) is a commonly prescribed antibiotic with a mean
peak plasma concentration of approximately 6 µg/mL (approx. 16 µM) (FDA). Drug treatment
ranging from 1-100 µM showed no apparent toxic effect on either structure or functions of the
cardiac organoids at all three tested concentrations. Although there is a slight effect on the beat
rate and beat duration, contraction velocities were not significantly impacted. In addition, the size
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and structure of the organoids was not impaired between controls and high concentration of 100
µM.

4.3.3

Cardiac organoid sensitivity to Category C - Rifampicin

Rifampicin (category C) (Figure 16) is also an antibiotic used to treat tuberculosis and meningitis.
Rifampicin administration in healthy adults can reach peak plasma concentrations ranging from 432 µg/mL (approx. 4.8-39 µM) (FDA). Treatment to cardiac organoids showed severe
developmental toxicity at a high concentration (100 uM) with no organoid formation. Specifically,
cells were not able to survive at this concentration, indicating an increasing degree of cytotoxicity
as the treatment concentration increased. This was especially seen at low and moderate
concentrations where the area ratio, height, and FWHM show a gradual decrease in all variables
relating to cardiac tissue formation.

4.3.4

Cardiac organoid sensitivity to Category D – Doxycycline

Doxycycline (category D) (Figure 17) is also an antibiotic used to treat a large variety of infections,
such as skin, respiratory treatment, sexually transmitted etc. Administration of doxycycline
produces a mean peak plasma concentration of 2.6 µg/mL (approx. 5.8 µM). Similar to rifampicin,
doxycycline also resulted in severe impairment on cardiac differentiation and organoid formation.
Effects of doxycycline, however, became apparent even at a moderate concentration of 10 µM. At
10 µM, cardiac organoids failed to produce a dome-like cardiac tissue structure, but rather formed
patch-like regions of cardiomyocytes. Because of this, the organoids were able to exhibit
contraction at this concentration, but Area Ratio and FWHM measurements could not be made
because there was no complete cardiac tissue structure. Also comparable to rifampicin, high
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concentration resulted in severe cytotoxicity, where cells died within 2 days after the drug was
first introduced. Therefore, we classified this drug as highly toxic, since failed to create 3D
organoids due to massive cell apoptosis at high concentrations.

4.3.5

Cardiac organoid sensitivity to Category D – Lithium Carbonate

Lithium carbonate (category D antidepressant) (Figure 18) exposure did not result in negative
effects to the contractile functions of the cardiac organoids but exhibited minimal toxicity to the
organoid formation measured by area ratio and FWHM. Surprisingly, exposure of lithium only
showed mild developmental toxicity manifested as slight reduction in cardiac differentiation and
organoid formation. No impairment was observed in contraction functions. However, lithium is
known to have a very narrow window of therapeutic concentrations, and there has been a long
debate of this drugs’ developmental toxicity, especially resulting in congenital heart defects93,94.

4.3.6

Cardiac organoid sensitivity to Category D - Phenytoin

Phenytoin (category D) (Figure 19) is prescribed as an anti-convulsant and muscle relaxant to treat
seizures. Therapeutic plasma concentrations range from 10-20 µg/mL (approx. 40-80 µM) (FDA).
Phenytoin exposure produced the cardiac organoids that were smaller than controls, but still
maintained structural integrity. However, the cardiac organoids were larger, but stopped beating
at a high concentration (100 uM), until the drug was removed to allow the organoids to recover
the contractile functions. We believe that the cardiac tissues were larger at high concentration
because the high concentration prevented contraction of the tissue, thus preventing tissue
compaction over time. When the drug was removed and replaced with fresh media, the organoids
began to contract after approximately one day. After equilibration over 3 days, the organoids at all
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concentrations exhibited comparable contraction physiology to controls. This confirmed that
phenytoin did not impair cardiac tissue development, but rather inhibited the muscle contractility
due to its muscle relaxant properties95,96.

4.3.7

Cardiac organoid sensitivity to retinoids Category D – Tretinoin and Category X –

Isotretinoin
Tretinoin (also known as all-trans-retinoic acid, category D retinoid) (Figure 20) and isotretinoin
(13-cis-retinoic acid, category X retinoid) (Figure 21) are both retinoic acid derivatives used to
treat severe acne. Isotretinoin is a metabolite of tretinoin, but both drugs can be prescribed
individually. Plasma concentration of tretinoin range from 1-3 ng/mL (approx. 0.01 µM), whereas
the plasma concentration of isotretinoin ranges from 300-800 ng/mL (approx. 1-2 µM) (FDA).
Although both drugs are similar, there is a high range in peak plasma concentrations. This, as well
as the presumptive safety category can be attributed to the method of administration, where
tretinoin is often prescribed as a topical gel, and isotretinoin is administered orally. Tretinoin
treatment completely abolished the cardiac differentiation at the highest tested concentration of 10
µM, but still produced the organoids with comparable height and overall size as controls. Since
retinoic acid derivatives are known compounds to cause fetal toxicity, we also tested isotretinoin
on the cardiac organoids. Similar to tretinoin, isotretinoin can produce large organoids at all tested
concentrations, but totally abolished the cardiac differentiation at even lower concentration at 1
µM. This implied that retinoids caused severe impairment to the cardiac differentiation, but did
not interfere with the tissue growth.

4.4

Embryotoxicity screening on developing myocardium of zebrafish embryos
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Last, we compared the developmental toxicity of these tested drugs between cardiac organoid
model and zebrafish whole embryo culture (zWEC), a well-established toxicity assay with
promising potential to screen for teratogenicity97,98. We used transgenic Tg(myl7:GFP) zebrafish99
that express GFP only in cardiomyocytes, which allowed us to readily score myocardial
development and heart tube looping at 48 hours post-fertilization (hpf)100 (Figure 22a). Live
zebrafish embryos were collected and exposed to the identical drugs at identical concentrations
used in the cardiac organoid assay. Consistent with the organoid model, exposure with doxylamine
succinate (Category A) (Figure 22b) had negligible effect on the zebrafish embryonic heart
development, as there was a significant proportion of embryos exhibiting normal D-looped heart
across all the concentrations. However, the effects of thalidomide (Figure 22c) on zebrafish
embryonic heart development were not as significant as what we observed in the organoid model.
We found that the proportion of normal heart looping did not significantly decrease at higher
concentrations of thalidomide.

Several of the other drugs (Figure 23) tested also showed meager embryotoxic effects to the
zebrafish embryos, including rifampicin (Figure 23b) and phenytoin (Figure 23d). Amoxicillin
(Figure 23a), lithium carbonate (Figure 23c) and doxycycline (Figure 23e) showed moderate
toxicity. In contrast, retinoic acid derivatives, tretinoin (Figure 23f) and isotretinoin (Figure 23g),
caused severe defects to the zebrafish embryo heart development. At low concentration (0.1 μM),
embryos had severe heart defects, including smaller size and abnormal morphology. At higher
concentrations, the hearts failed to develop, as indicated by 0% of embryos expressing the GFP
transgene. This result was comparable to effects that we observed in the organoid model, which
was a lack of cardiac development at higher dose. Upon comparing the organoid model with the
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zWEC model, we saw developmental toxicity that was comparable for both systems for most of
drugs (doxylamine succinate, amoxicillin, lithium carbonate, phenytoin, tretinoin, and
isotretinoin). However, rifampicin, doxycycline and thalidomide showed distinct mismatch
between these two model systems. We infer that this is due to a number of factors, including
species differences, method of drug exposure, and differences in the range of effective treatment
concentrations.

4.5

Conclusions and discussion

In this study, the cardiac organoid model allowed us to evaluate human-specific drug-induced
developmental toxicity based on disruption of forming correct 3D organoid structures and
developing normal cardiac contractile functions. By exposing the cardiac organoids to a range of
drugs with different risk categories, we found an overall increase of teratogenic severity on cardiac
organoid formation, corresponding to the increase of test concentrations, as well as the increase of
risk category from A to X. Category D drugs (phenytoin, lithium, doxycycline and tretinoin)
showed diverse effects on developmental toxicity. Three antibiotic drugs tested on the cardiac
organoids showed increased developmental toxicity with the increase of their risk classification in
the pregnancy category. Continuing testing another three category D drugs on the organoids, we
found variations in the levels of developmental toxicity on both tissue morphology and contractile
functions. Overall, these results verified that this cardiac organoid model was sensitive to the druginduced developmental toxicity, thus offering the capability of morphological scoring based on the
3D tissue formation, which is often not available from other stem cell-based in vitro assays.
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Upon the comparison between human organoid model and traditional zebrafish whole embryo
culture (zWEC) assay, we observed that three drugs (thalidomide, rifampicin, and doxycycline)
resulted in opposed toxicological responses, where cardiac organoids manifested severe
morphological impairment, while zebrafish embryos only showed mild effects. Thalidomide, a
known teratogen commonly used as a positive control, has demonstrated variable effects in
different embryotoxicity assays. The developmental toxicity of thalidomide on zebrafish embryos
has been documented to stunt fin development and inhibit angiogenesis, but only with higher
concentrations (at least double the highest concentration of our study)101,102. In a comparative
study, a 2D hiPSC-based model demonstrated stronger embryotoxic responsiveness to thalidomide
exposure than the mouse embryonic stem cell test (mEST), highlighting the differences in druginduced developmental toxicity due to the species differences88. Rifampicin and doxycycline,
however, have not been extensively studied for the potential of developmental toxicity with new
human-based screening methods, such as hESC or hiPSC tests. For instance, rifampicin was used
as an up-regulator of CYP genes in the zebrafish and PSC-derived tissues to enhance drug
metabolism103, without explicit characterization for its embryotoxic potential. On the other hand,
doxycycline, commonly used as an inducer for Tet-ON activation, has shown to enhance hiPSC
survival and renewal at low concentrations (< 20 μM)104. However, doxycycline has been
documented to induce fetal loss in live mice after administration of the drug for Tet-ON
activation105. Although we have presented a relatively simple experimental design to demonstrate
the sensitivity and responsiveness of the cardiac organoid model to a variety of drugs, the drug
concentrations can be tailored to match physiological concentrations in amniotic fluid that the
developing human embryo would be exposed to.
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Figure 14. Cardiac organoid developmental toxicity to doxylamine succinate and
thalidomide. (a) The timeline of cardiac organoid generation and continuous drug exposure. Epifluorescent microscopy images of the cardiac organoids for comparison between untreated controls
with (b) doxylamine succinate (category A drug) and (c) thalidomide (category X drug). The area
ratio of cardiac muscle coverage showed (d) an increase with doxylamine succinate (n = 29, *p ≤
0.0001), but a decrease with thalidomide at high concentrations (n ≥ 28, *p ≤ 0.0001). The
contraction velocity of cardiac contractile motion showed no drug effect from (f) either
doxylamine succinate (g) or thalidomide. The beat rate showed (h) a decrease with doxylamine
succinate (n ≥ 9, *p ≤ 0.0001), and an increase with thalidomide at 1 µM and 10 µM concentrations
(n ≥ 12, *p ≤ 0.0001). (j) The cardiac organoids under doxylamine succinate exposure showed no
drug effects on the 3D organoid morphology at all the tested concentrations. (k) Thalidomide
exposure induced significant structural impairment on 3D organoid formation, showed as lower
height (n ≥ 9, *p ≤ 0.0001) and FWHM (n ≥ 14, *p ≤ 0.0001) at high concentrations. Representative
confocal microscopy images of the cardiac organoids of (k) untreated control and (m) 100 µM
thalidomide exposure showed severe abnormal organoid formation for quantitative morphological
scoring.
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Figure 15. Developmental toxicity assay of cardiac organoids in response to treatment with
Amoxicillin (Category B). Amoxicillin showed moderate toxicity with decreased beat rate (twoway student t-test, n ≥ 11, *p = 0.0048) and increased beat duration (two-way student t-test, n ≥
11, *p = 0.0013) at high concentrations. Amoxicillin treatment at low concentrations, however,
produced smaller cardiac tissues in area ratio (two-way student t-test, n ≥ 18, *p = 0.0083 between
Controls and 1 µM) and in height (two-way student t-test, n ≥ 7, *p ≤ 0.0001).

54

Figure 16. Developmental toxicity assay of cardiac organoids in response to treatment with
Rifampicin (Category C). In all assays, cardiac organoids failed to differentiate at 100 µM
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 12,
*p = 0.0174), beat rate (two-way student t-test, n ≥ 12, *p = 0.0232), area ratio (two-way student
t-test, n = 29, *p = 0.0123), height (two-way student t-test, n ≥ 10, *p ≤ 0.002 relative to controls)
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001).
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Figure 17. Developmental toxicity assay of cardiac organoids in response to treatment with
Doxycycline (Category D). In all assays, cardiac organoids failed to differentiate at 100 µM
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 7, *p
= 0.0036), beat rate (two-way student t-test, n ≥ 7, *p ≤ 0.0067), beat duration (two-way student ttest, n ≥ 7, *p ≤ 0.0001), and height (two-way student t-test, n = 8, *p ≤ 0.0061 relative to controls)
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001).
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Figure 18. Developmental toxicity assay of cardiac organoids in response to treatment with
Lithium carbonate (Category D). No significant toxicity effects were seen in any contraction
function. However, moderate toxicity was seen in all concentrations for the area ratio (ANOVA,
n ≥ 26, *p ≤ 0.0001) and in FWHM (ANOVA, n ≥ 20, *p ≤ 0.0001) relative to the controls.
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Figure 19. Developmental toxicity assay of cardiac organoids in response to treatment with
Phenytoin (Category D). Phenytoin showed no contractile functions at 100 µM concentration,
with moderate effects at 1 µM on beat rate (two-way student t-test, n ≥ 11, *p = 0.0165) and beat
duration (two-way student t-test, n ≥ 11, *p = 0.0101). Organoids were also smaller in area ratio
at 10 µM treatment (two-way student t-test, n = 28, *p = 0.0006) and smaller at all concentrations
in height (ANOVA, n ≥ 12, *p ≤ 0.0001) and FWHM (ANOVA, n=20, *p ≤ 0.0001) relative to
controls.
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Figure 20. Developmental toxicity assay of cardiac organoids in response to treatment with
Tretinoin (Category D). Cardiac tissue failed to develop at 10 µM concentrations with no
contraction functions. Contraction velocity was lower at 0.1µM (two-way student t-test, n ≥ 7, *p
= 0.0274), whereas beat rate was faster at 0.1µM and 1 µM (ANOVA, n ≥ 7, *p = 0.0001). Beat
duration was significantly lower at 1 µM (two-way student t-test, n ≥ 7, *p ≤ 0.0001) as well. Low
concentration of 0.1 µM also showed toxic effects on area ratio (two-way student t-test, n ≥ 12, *p
≤ 0.0112), height (two-way student t-test, n ≥ 8, *p = 0.0004), and FWHM (two-way student ttest, n ≥ 12, *p ≤ 0.0001).

59

Figure 21. Developmental toxicity assay of cardiac organoids in response to treatment with
Isotretinoin (Category X). Cardiac tissue failed to develop at 1 µM and 10 µM concentrations
with no contraction functions. Low concentration of 1 µM resulted in faster beat rate (two-way
student t-test, n ≥ 13, *p ≤ 0.0007) and smaller area ratio (two-way student t-test, n ≥ 31, *p ≤
0.0001). However, high concentrations produced organoids that were significantly taller in height
(ANOVA, n ≥ 9, *p ≤ 0.0001) and larger in FWHM (ANOVA, n ≥ 12, *p ≤ 0.0001).
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Figure 22. Cardiac looping scored as a cardiac developmental toxicity evaluation in the
zebrafish whole embryo culture assay (zWEC). Zebrafish embryo heart structures were scored
based on loop structure, where (a) D-looped heart structures are the normal expected structure. No
significant drug effect from (b) doxylamine succinate exposure, and a very mild toxicity level from
high dosage exposure of (c) thalidomide. A sample size of n>40 embryos were analyzed for these
treatment groups.
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Figure 23. Zebrafish whole embryo culture (zWEC) assay of cardiac looping for seven drug
compounds. (a) Category B amoxicillin and (b) Category C rifampicin produced mild
developmental toxic effect. (c-f) Category D drugs displayed developmental toxic effects ranging
from moderate (lithum carbonate, phenytoin, and doxycycline) to severe (tretinoin). (g) Category
X isotretnoin produced severe developmental toxic effects at all concentrations. (h) Morphological
scoring was performed on heart structures of developing zebrafish embryos based on either normal
(D-loop), reverse (L-loop), no loop, or no score where the heart did not express GFP and/or fall
into the previous three categories. A sample size of n>19 embryos was used for all treatment
groups.
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Table 3. List of drug compounds with medicinal uses and previously designated pregnancy
category
Drug

Medicinal Use

Pregnancy
Category

Concentrations Tested

Doxylamine Succinate

Antihistamine, sleeping aid

A

1 μM, 10 μM, 100 μM

Amoxicillin

Antibiotic (strep, middle ear
infections etc.)

B

1 μM, 10 μM, 100 μM

Rifampicin

Antibiotic (TB, leprosy etc.)

C

1 μM, 10 μM, 100 μM

Lithium Carbonate

Bipolar antidepressant

D

1 μM, 10 μM, 100 μM

Phenytoin

Anticonvulsant

D

1 μM, 10 μM, 100 μM

Doxycycline

Antibiotic

D

1 μM, 10 μM, 100 μM

All-trans-RA
(Tretinoin)

Acne treatment

D

0.1 μM, 1 μM, 10 μM

13-cis-RA
(Isotretinoin)

Acne treatment

X

0.1 μM, 1 μM, 10 μM

Thalidomide

Myeloma, Inflammation

X

1 μM, 10 μM, 100 μM
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5. Chapter 5: Single cell characterization of cardiac organoids using
next generation sequencing technologies

Overview
This Chapter discusses the characterization of cardiac organoids at single cell genomic resolution.
The goal of this study was to analyze the single cell genomic profiles that compose cardiac
organoids using single cell RNA sequencing (scRNAseq). We performed scRNAseq and
bioinformatics data processing to identify cell populations obtained from the cardiac organoid
arrays. Since scRNAseq requires high quality cells at high viability, preliminary studies were first
performed to assess cell viability after dissociation and flow cytometry analysis. scRNAseq was
proposed because the organoid field is currently taking advantage of this technology to
characterize cell types generated in stem cell-derived organoids. This allows us to study the
organoid function based in individual cell contributions as well as characterize the extent to how
organoids recapitulate in vivo tissue.

5.1 Motivation
Mammalian heart development is governed by complex signal transduction pathways that drive
the transformation of a linear heart tube into a four-chambered heart106. In addition, these processes
involve different cell types, including cardiomyocytes, endocardial cells, epicardial cells, and
smooth muscle cells that synergistically perform specific functions essential to heart
development107. Use of next generation sequencing technologies has been growing at an
exponential rate over recent years because of its powerful ability for high throughput study of the
genomic profiles and functions of individual cells108, which gives important insight on cell
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populations within a tissue, especially for stem cell-derived tissue models. More specifically,
scRNAseq has been applied to identify cell diversity within complex tissues109, including brain
organoids110–114, gut organoids115,116, as well as in murine and human myocardium106,107,117,118.

From the IHC characterization, the region-specific staining patterns indicate two primary cell types
within the cardiac organoids. However, this does not illustrate the potential diversity of these types,
or the rare and unknown cell subtypes that may also exist. Flow cytometry (FACS) was first used
to provide preliminary data to approximate cell viability as well as the approximate the cell
population fractions that we can expect to see with scRNAseq. FACS, however, is limited to only
a small number of protein markers that can be tagged, which only provides a simple quantification
of the fraction of cells expressing those specific markers. This cannot output the in-depth genomic
profiles that scRNAseq can provide, which is a high-resolution profile of each cell that will allow
the segregation of cells based on common expression patterns of all sequenced genes. scRNAseq
will supply more definitive classification of cells that compose the organoids. This will provide
insight on the embryonic profile of the cardiac organoids so that their respective stages can be
cross-referenced with the corresponding stages in mammalian heart development.
5.2 Cardiac organoid characterization
5.2.1 Cardiac organoid dissociation
The cardiac organoids generated using the method described in Chapter 2 results in tissues that are
adhered to TCPS. As such, the organoids require dissociation and singularization for scRNAseq
analysis. The organoids were generated using 600 um patterns and sacrificed on Day 20. Organoids
were then isolated by physical scraping off excess residual cells and tissue that can potentially
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skew the single cell profiling of the organoids. The organoids were then dissociated for 10 minutes
using 0.25% Trypsin and quenched with FBS supplemented media.
5.2.2 Characterization using flow cytometry
After pelleting and resuspension, the cells were strained to further singularize cell clusters.
Singularized cells were prepared for FACS analysis by fixing with 4% paraformaldehyde and
stained with cardiac troponin T (cTnT) antibody (cardiac marker) and vimentin antibody (stromal
marker). FACS analysis showed that approximately 80% of cells are positive for vimentin and
50% of cells are positive for cTnT. However, repeats of these studies showed inconsistency and
high variability with the marker distributions.
5.2.3 Assessment of cell viability of singularized organoids
Cell viability was carefully addressed, since the quality of cells can have significant impact on the
cellular expression profiles in scRNAseq. In addition, all genomics sample processing was to be
performed at the Cornell Biotechnology Resource Center (BRC) (Figure 24), which requires
approximately 1.5 hours of transportation time. After consultation, the recommended cell viability
should be at least 50%. The viability of the organoids was assessed immediately after straining
and at 30 minute intervals over a 2-hour time period using automated cell counting. During this 2
hour period, the cells were stored on ice and supplemented with 1% HEPES buffer, as it is often
recommended to promote cell survival over long periods of time. After 2 hours, the cell viability
was negligibly affected, remaining at approximately 80% viable cells. This preliminary study
showed that the dissociation and singularization did not significantly impact cell integrity and was
sufficient for sample processing at the Cornell BRC.
5.3 Single cell RNA sequencing of cardiac organoids
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5.3.1 scRNAseq data acquisition and pre-processing
Organoids from 600 um patterns were used for initial preliminary scRNAseq processing. Cells
were dissociated and singularized following the procedure outlined in the previous section
(Chapter section 5.2). Library preparation, sequencing, and alignment of reads was performed
following a standard 10X Genomics pipeline (Figure 24a). Libraries were prepared from the 10X
Genomics Chromium, followed by a sequencing run of 75 base pairs (Illumina NextSeq500). Raw
reads were processed using the CellRanger analysis pipelines to demultiplex, align, and filter gene
expression reads for downstream analysis. From this initial experiment, the output data consisted
of 4805 cells. The read count of these cells ranged from 500 to 194,572 counts, with the number
of detected genes ranging from 43 to 11,308 features.

Preprocessing analysis was carried out using Partek Flow, courtesy of a shared license provided
by the SUNY Upstate Medical University Genomics Core. Single cell RNA sequencing data
contains noise as well as reads from low quality cells as a result from sample preparation
procedures required. Preprocessing of data consists of various steps to normalize and filter cells
and genes to include only high-quality cells that can provide optimal biological information. The
single cell data was normalized using default recommended parameters (counts per million, Add
1, Log2). Single cell QA/QC was then performed to filter out low quality cells. Cell quality was
assessed based on violin plot distributions of read counts (Figure 24b), detected features (Figure
24c), and percentage of mitochondrial counts (Figure 24d). From the distribution plots, cells were
downscaled to ~3000 cells, which include those with read counts greater than 2800, detected genes
greater than 1300, and mitochondrial counts of less than 30%.
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The primary goal of this chapter is to identify cell populations within the total pool of cells. We
based our study criteria to only include genes that are differentially expressed within the entire
pool of cells. Therefore, we chose to apply a statistics-based filter based on variance of the detected
genes, which will identify differentially expressed genes. As the cell populations within the cardiac
organoids are unknown, we assumed that genes with high variance would distinguish one cell
population from another. The feature filter was applied to only include the top 1000 genes with
the highest variance. This filter removes most genes from downstream analysis, but particularly
genes that have comparable expression profiles between all cells. These commonly expressed
genes are often involved in metabolic and general cell functions, which do not provide information
on the distinct functions of a specific cell type.

5.3.2 Downstream processing of scRNAseq data
The previous section 5.3.1 outlines necessary processing steps to clean and optimize raw
scRNAseq data output for downstream applications to be performed on Partek Flow. These
downstream processes include clustering, differential expression, pathway, and trajectory analyses
to classify cells within the population, as well as gain higher-level biological insight exhibited by
cardiac organoids. Principal component analysis was first applied to reduce the data
dimensionality. Graph-based clustering was then applied to segregate cells within the population
into specific groups of which cells within that group exhibit similar expression profiles. Using the
600 µm cardiac organoids, the graph-based clustering method identified approximately ten cell
populations within the sample. These clusters were then visualized with T-distributed stochastic
neighbor embedding (t-SNE) (Figure 24e), where each dot corresponds to an individual cell
belonging to an assigned cluster based on the specified color. Cells can also be visualized using
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trajectory analysis (Figure 24f), which aligns each cell along a trajectory branch that corresponds
to a cell state. Cells from the organoids aligned along a three-branch trajectory, meaning that the
cells are primarily in three different states. We examined the differential gene expression profiles
of cell clusters along each branch and inferred that the three primary states are cardiac, endodermal,
and stromal cell lineages.

5.3.3 Classifying cardiac organoid cell type composition
We first confirmed the presence of the two known cell types, both cardiomyocytes and smooth
muscle-like or stromal cells, which were identified from immunofluorescence staining
characterization used in previous chapters. Using the t-SNE plot, cells were highlighted based on
their expression of known specific markers of the cells of interest. MYH6, ACTN2, and MYBPC3
were used as cardiac markers and the expression of these genes was concentrated in clusters 1 and
7 (Figure 25a, b). Next, we profiled the expression of TAGLN2 and ACTA2, which are smooth
muscle markers that were used in previous immunofluorescence characterization (Figure 25c, d).
These genes exhibited scattered distribution across multiple cell clusters. Violin plot expression
profiles of TAGLN2 across all cells illustrated the highest expression in all clusters except for 1
and 7, these of which were determined as the cardiomyocyte populations. This verified that the
organoids were composed of cardiomyocytes and stromal-like cells, as predicted.

The differentially expressed genes were then visualized using heat maps and hierarchical
clustering of the genes to compare gene expression profiles across clusters (Figure 26). We
generated a gene heat map and performed hierarchical clustering on a reduced list of the top 100
genes with the highest variance. To further classify the cell populations, we evaluated the genes
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with the highest scaled expression based on the standardized z-score, indicated by the red coloring
on the heat map, as these genes are likely the features that distinguish one cell cluster from another.
For cardiomyocyte cell populations 1 and 7, MYL3 is downregulated in cluster 7 and upregulated
in cluster 1. This suggests that cluster 1 cells are ventricular-like cardiomyocytes, as MYL3 is a
specific marker for cardiac ventricular muscle119. Therefore cluster 7 are likely atrial-like
cardiomyocytes, or immature fetal striated muscle cells. This trend can also be seen in the
trajectory plot, where cluster 7 cells are not as concentrated or as far along the branch as cluster 1.

Genes that were upregulated in cluster 2 are involved in tissue morphogenesis and growth (VCAN,
PLAC9, IGFBP2). Additionally, cardiac specific genes were also upregulated, relative to the
remaining non-cardiomyocyte clusters. Therefore, we inferred that cluster 2 is a population of
progenitor cells with the potential for cardiac specificity. Clusters 3, 5, and 8 showed similar
expression profiles, particularly for genes directly involved in collagen production (COL1A2,
COL3A1, COL1A1). This corresponds to stromal cells, including fibroblasts and smooth muscle.
From the heat map, ACTA2, TAGLN, and MYL9 were differentially expressed in cluster 5 only,
suggesting that these cells are likely smooth muscle cells, while clusters 3 and 8 are subtypes of
stromal cells.

Interestingly, we classified multiple clusters of cells of endodermal lineage. This is attributed to
the differentiation protocol, which specifically targets Wnt signaling that also plays a role in
regulating endoderm patterning120,121. Additionally, liver development is facilitated through
synergistic paracrine signaling with the heart122, which can explain the endodermal specification
in the cardiac organoids. Clusters 4 and 6 expressed upregulated genes related to endodermal and
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epithelial cell lineages (EPCAM), but also genes related to immune cell inflammatory response
(ALB, CD24, and FGG). Lastly clusters 9 and 10 had the fewest distinguishable gene expression
patterns based on the heat map, likely because these populations had the fewest cells. However,
from the trajectory plot, these clusters were scattered along the same branch state as clusters 4 and
6, implying a relation between these four clusters.

5.4 Single-cell genomics characterization of cardiac organoid lineage specification directed
by geometry size
To study how geometric confinement affected the cell fate choice of cardiac organoids, we profiled
the gene expression of organoids generated from 200 μm, 600 μm, and 1000 μm diameter circular
patterns with single cell RNA sequencing. Ten unique cell populations were identified (Figure 27)
using integrated datasets of these three shapes (63,175 cells). Cell populations were determined
using a differential gene expression filter of the 1000 genes exhibiting the highest variance,
followed by principal component analysis and graph-based clustering. Trajectory analysis was
then performed, which classified the cells into the three primary cell lineages that cardiac
organoids exhibit (cardiac, stromal, or endodermal) (Figure 28a). Individual cell clusters from
these lineages were classified by identifying the presence of and assessing the expression gradients
of cell specific markers that are unique to these three lineages (Figure 28c, Figure 29). Three cell
types within the cardiac lineage branch were classified as two populations of cardiomyocytes
(atrial-like and ventricular like) and cardiac-mesodermal progenitor cells. Cells along the
endoderm branch were classified as hepatocyte-like cells, hepatoblast-like cells, hepatic epithelial
cells, as well as endoderm and mesoendoderm progenitor cells. Lastly, cells along the stromal
branch of the trajectory were composed of fibroblast and smooth muscle-like cells, but very few
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expressions of vascular endothelium (KDR, FLT1, ICAM, PECAM, CDH5). Meanwhile, these
stromal cells showed affinity to produce signaling factors promoting the hepatic epithelium
development (HGF). Expression pattern of transcription factors (TBX) and signaling molecules
related to WNT and BMP signaling cascade were primarily sequestered towards either cardiac or
hepatic cell lineages. For instance, the HHEX activation seen in endodermal cells is likely
facilitated by the high BMP signaling from cardiac cells123. This suggested that the organoids
exhibited a high degree of paracrine signaling occurring to promote both cardiac and hepatic
development.

Two major cell clusters containing ~68% cells are cardiomyocytes and hepatic epithelium. More
importantly, each of these two clusters were further divided into two sub-clusters based on the
pattern sizes (Figure 30). Comparing 200-µm pattern with 600-µm and 1000-µm patterns, the
cardiomyocyte population was clearly separated between pattern sizes (blue v.s. green) due to the
different expression level of cardiac-specific genes. This was also observed on the hepatic
epithelial cell population (red v.s. purple). The organoids generated from the 200 µm patterns
contained the cardiomyocytes (blue) and hepatic epithelial cells (purple) at the early differentiation
stages, meanwhile they also had larger populations of progenitor cells (cardiac mesoderm, hepatic
endoderm and mesoendoderm-like cells), in comparison to the 600-µm and 1000-µm organoids.
This indicated that small organoids were delayed in the differentiation of organ-specific cell types,
and also retained large population of premature cell types. Mid-sized organoids from 600 µm
patterns had the largest fraction of late differentiated cardiomyocytes and smooth muscle-like cells,
and fewer progenitor cells and endodermal cells, indicating a high-efficiency in muscle
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specification. In contrast, large organoids from 1000 µm patterns, promoted greater differentiation
into endodermal and hepatic cell populations.

Hierarchical clustering and gene ontology (GO) pathway analysis were performed to assess
specific biological processes between cell types (Figure 31). GO analysis of the cardiomyocyte
populations showed high specificity for heart-related functions, such as regulation of heart
contractions and cardiac muscle tissue morphogenesis. Pathways related to the progenitor cells
indicated less specific cell functions, indicating that these cells are not yet organ-specific and are
likely premature. Lastly, pathways corresponding to endodermal cells were related to liver,
metabolic and endocrine processes. By comparing the sizes with genes specific to each of the three
primary cell lineages (cardiac, endodermal, and stromal) (Figure 32), genes related to cardiac
development were expressed to a higher degree in the 600 µm organoids. In contrast, smaller 200
µm patterns produced the organoids with high expression of the genes related to stromal cells,
while larger 1000 µm patterns produced the organoids with high expression of the genes related
to hepatic development. Although our protocol was targeted to the cardiac muscle differentiation,
these results indicated that the influence of geometric size on the co-emergent cell lineage
transition from stromal cells with small organoids, to cardiac mesoderm with mid-size organoids,
and to hepatic endoderm with large organoids.

5.5 Conclusions and discussion
In this study, we profiled the cellular diversity of the cardiac organoids using scRNAseq and
bioinformatics analysis. Cells that compose cardiac organoids are a result of three primary cell
lineages: cardiac, stromal, and endodermal cells. In addition, we profiled the cellular diversity
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resulting from organoids generated in different circular sizes and observed lineage specification
that is driven by the geometric size. We found that cardiac lineage specification was optimized in
mid-sized (600 µm diameter) organoids, which supports previous structure and function
characterization of size effects on organoid production discussed in Chapter 3. Small organoids
(200 µm diameter) promoted differentiation into progenitor-like cells, whereas large organoids
(1000 µm diameter) promoted a high percentage of endodermal cell differentiation.

The attributes unique to the 200 µm organoids suggests that small confinement directs cells to
differentiate into progenitor-like cells that are less specific and do not have gene expression
patterns indicative of terminal cell types. This shape also produced organoids composed of
cardiomyocytes that differ from the targeted ventricular cardiomyocytes, suggesting that very
small confinement size can influence the cardiomyocyte differentiation trajectory. These attributes
can also be associated with the inability of cardiac organoids to consistently and reliably
differentiate in this size, as these organoids display the highest variabilities in 3D structure,
contraction functions and differentiation efficiency. Mid-sized 600 µm organoids produced the
largest fraction of ventricular-like cardiomyocytes, indicating an optimal size for cardiomyocyte
differentiation to compose the organoids. This data supports the analysis of the structural
morphology of cardiac organoids relative to size, where 600 µm organoids exhibited the largest
3D architecture based on imaging analysis and staining patterns of cardiomyocyte specific
markers. From the t-SNE plots, 1000 µm organoids also displayed a comparable density of
ventricular cardiomyocytes to 600 µm organoids, but at a lower percentage due to the strong
promotion of endodermal cells. Comparable cardiomyocyte differentiation can be correlated with
the structural analysis of the organoids, where organoid sizes greater than 600 µm did not have
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enhanced 3D cardiac structure, relative to 600 µm organoids, as the size increased. This suggested
that cardiomyocyte differentiation reaches a limiting point that is controlled by geometry.

Since organoids models are hypothesized to model organ development and functions, utilizing
scRNA-seq is a powerful tool to understand the degree of developmental recapitulation114,115,124.
In cardiac development, scRNA-seq has facilitated the identification and mapping of rare cell types
that can uncover biological mechanisms involved in disease125. Based scRNA-seq of the human
fetal heart117,118, the cardiac organoids are able to recapitulate multiple major cell types that were
seen in human embryos, including cardiomyocytes smooth muscle cells and cardiac fibroblasts,
but lack of epicardial development and vasculogenesis. Interestingly, though our differentiation
protocol primarily focuses on the cardiac lineage induction, the formation of cardiac organoids
resembles the co-emergent cell induction into both cardiac and hepatic lineages, which was also
observed from other organoid models126. Due to the close proximity in embryo development,
paracrine signaling from the heart facilitates the specification of hepatic epithelium from endoderm
layer, which is the first step of liver development122,127. Our results not only indicated that parallel
multi-lineage specification of the heart-liver synergy that occurred in our cardiac organoid model,
but also demonstrated that external biophysical cues can modulate these co-emergent
developmental processes.
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Figure 24. Single-cell RNA sequencing and bioinformatics workflow. (a) Single-cell RNA
sequencing pipeline using 10X Genomics from sample preparation to data output using
CellRanger. Single cell data is plotted as a series of violin plots for quality control. Quality control
of output data involves filtering of (b) read counts, (c) detected features, and (d) percent
mitochondrial counts. Single cell data is then clustered into cell types based on PCA
dimensionality reduction and visualized using (e) t-SNE and (f) trajectory trees to identify cell
types.
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Figure 25. Cell-specific gene identification of cardiomyocytes and stromal cells. (a)
Cardiomyocytes were identified by locating the cell cluster expressing cardiomyocyte markers
ACTN2, MYBPC3, and MYH6. (b) MYH6 expression showed to be highly specific to clusters 1
and 7, identifying two sub-populations of cardiomyocytes. (c) Stromal cell markers TAGLN2
and ACTA2 confirmed the presence of stromal cells and (d) displayed scattered expression
across multiple cell clusters, except in the cardiomyocyte populations.
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Figure 26. Heat map of top one hundred differentially expressed genes for cell cluster
classification. Genes were filtered to only include the top 100 genes with the highest variance.
These differentially expressed genes were used to approximate the classification of the cell type
composing each cluster.
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Figure 27. Integrated t-SNE plot of classified cell clusters composing 200 µm, 600 µm, and
1000 µm cardiac organoids. t-SNE plot of cells (>63,000) colored by cell type. Cells were
clustered based on PCA and graph-based clustering.
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Figure 28. Classification of cell clusters using trajectory analysis and identification of cellspecific genes. (a) Trajectory analysis of cardiac organoids of different sizes fall in three primary
cell lineage branches: cardiac, stromal, and endodermal. (b) Lineage specific markers were
mapped to locate and further classify the cell populations illustrated within the t-SNE.
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Figure 29. The t-SNE expression maps for vasculogenic, cardiogenic, and hepatogenic
signaling factors in the cardiac organoids. Cardiac organoids showed low indication of
vasculogenesis, but high indication of paracrine signaling between mesodermal cardiac lineages
and endodermal hepatic lineages
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Figure 30. Fractional composition of cell types in small, mid-size, and large organoids.
Cardiac organoids of different sizes drive differential cell specification. Small organoids (200
micron) had higher fractional compositions of early cell types and progenitor cells. Mid-size
organoids (600 micron) had the highest fraction of cardiomyocytes and smooth muscle cells.
Large organoids (1000 micron) had the highest fraction of endodermal cells.
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Figure 31. Heat map and pathway analysis of cardiac organoid cell types. Gene ontology
pathway analysis was performed using a range of 10-20 genes for each major cell cluster.
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Figure 32. Cardiac, stromal, and endodermal gene expression patterns relative to cardiac
organoid size. Fold change expression patterns were plotted to compare gene expression across
the three pattern sizes. Genes were selected based on specificity to cardiac, endodermal, and
stromal cell lineages.

84

6. Chapter 6: Quantitative characterization of drug-induced cardiac
arrhythmias using nonlinear computational tools

Overview
In this Chapter, we describe computational workflow based on nonlinear phase space
reconstruction (PSR) to depict the deterministic dynamics of chaotic nature in the contractile
motions of cardiac tissues before and after drug administration. Through PSR, one-dimensional
(1D), or linear time-series signals can be mathematically modeled in high-dimensional space to
derive parameters for signal characterization. The new algorithm provided by a collaborative effort
with Professor Sabir Jaquir (Université Paris-Sud, Université Paris-Saclay, Neuro-PSI) presented
an analytical tool to quantitatively classify the arrhythmic contractile motions of hiPSC-CMs for
more precise drug cardiotoxicity screening. By integrating hiPSC technology, optical flow
computation and this new analytical tool, we envisage to measure abnormalities in heart
contraction related to drug-induced arrhythmia in an automated, high-throughput and quantifiable
manner128,129.

6.1

Background and rationale

Over recent years, there has been increasing interest of using nonlinear analysis to study human
biological signals, since maintenance of stability in physiological functions involves
interconnected feedback loops between biological systems. Such high degrees of interdependency
require in-depth investigation on the level of complexity and variability of the biological systems
for better understanding of their regulatory mechanisms. Cardiac rhythm has gained widespread
attention, because it is known to exhibit considerable signal complexity in healthy individuals from
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normal day-to-day activities. Additionally, cardiovascular diseases are often associated with
irregularities in cardiac contraction, frequency and rhythm130.

Cardiac physiology is traditionally quantified using linear analytical approaches that analyze
cardiac signals (e.g. electrocardiograms (ECG)) in the time and frequency domains131–133,
including optical flow contractile motion tracking (Chapter 2). However, current optical flow
analysis suffers from simplified conventional analytical tools of dominant frequency analysis132
and amplitude analysis133, providing time-series waveforms with measurement of beat rate,
contraction velocity, relaxation velocity and beat duration. Such analysis cannot faithfully predict
the complex biological behaviors and physiological signals to determine and classify the level of
arrhythmic contraction response to drug interference quantitatively, statistically and
systematically.

There is increasing evidence suggesting that nonlinear analysis can be used in conjunction with
standard diagnostic methods to quantify individual physiological states134. Differences in the
nonlinear indices can be monitored between healthy and sick individuals, including cases of
emotional stress, environmental changes, or genetic cardiomyopathies. Methods from chaos theory
and nonlinear dynamics give us the opportunity to study these complex biological signals,
including entropy135, complexity indexes136 and dimensional analysis137. Specifically, the phase
space consists of a set of typical trajectories of the system, in which each point corresponds to one
system state. The nonlinear properties, therefore, are a representation of the degree of regularity
and complexity of a signal. Analyzing the dynamic properties of a waveform represents a useful
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tool for identifying the number of independent variables necessary for generating a corresponding
process or state.

Nonlinear analysis based on PSR has previously been applied to analyze electrophysiological
signals to identify arrhythmia both in vitro and in vivo. Electrical field potentials from nrCMs
recorded by MEA were subjected to PSR to compute the parameters that quantified the unique
dynamics of normal versus arrhythmic signals138,139. PSR was also used to analyze heart rate
intervals of electrocardiograms (ECGs)140,141 and magnetic resonance image (MRI) data142
acquired from patients with different heart pathologies. The parameters computed from PSR, such
as embedding and correlation dimensions, varied considerably between groups with different heart
diseases, further reiterating the ability of PSR to quantitatively measure the dynamics of cardiac
signals140.

Despite the application of nonlinear analysis to the clinically acquired signals (e.g. ECG), such
analysis has not been widely applied for in vitro cardiac model systems. With the rising interest in
human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (hiPSC-CMs), it is of utmost
importance that we are able to characterize their contractile functions and heartbeat rhythm in a
more precise and comprehensive manner. However, current approaches to characterize the
contractile physiology of hiPSC-CMs still heavily depend on amplitude133 and frequency132
analyses of physical and electrophysiological data. These conventional analytical tools only draw
simplified readouts from complex biological signals. This poses the challenge of gaining
informative analytical outcomes from hiPSC-CMs to assess comparability with native tissue and
responsiveness to external stress143. In addition, hiPSC-CMs exhibit higher variability144,145 in their
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contractile behaviors than the adult human heart even under normal conditions, which further
emphasizes the need to integrate novel analytical methods to in vitro cardiac model systems.

To address this limitation, we took advantage of mathematical chaos theory to identify the
nonlinear dynamic characteristics of hiPSC-CMs contractile motions recorded using optical flow
and block-matching methods. More specifically, a phase space reconstruction (PSR) method141,146–
148

was used to convert our biological dynamic system into a phase space consisting of a set of

typical trajectories, in which each point is corresponding to a system state.

6.2

Materials and methods

6.2.1

hiPSC-CM differentiation, video microscopy and motion tracking

hiPSCs were first seeded onto Matrigel-coated -6-well tissue culture plates at 25,000 cells/cm2 and
cardiac differentiation was performed via modulation of the canonical Wnt signaling pathway64
outlined in Chapter 2.3.3. Video recordings of the beating hiPSC-CMs were taken at standard
physiological conditions and at 100 fps, followed by motion tracking analysis, as discussed in
Chapter 2.4.1.

6.2.3

Calcium flux imaging and analysis of GCaMP6f hiPSC-CMs

For calcium flux imaging, GCaMP6f hiPSC-CMs were generated from GCaMP6f hiPSC line with
the same differentiation protocol. GCaMP6f hiPSC-CMs can activate the fluorescence from green
fluorescent protein as an indication of the increased cytoplasmic calcium levels that occur during
hiPSC-CM contraction. The calcium flux images were recorded at 30 frames per second for 10
seconds and exported as single frame images. The fluctuations in fluorescent intensity were plotted
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by the Z-axis profile in ImageJ, corrected the fluorescent bleaching decay by in-house MATLAB
script, and analyzed by phase space reconstruction algorithm. For drug response studies, we
recorded the baseline contraction in both brightfield transmitting light for motion analysis and the
fluorescence emitted by the GCaMP protein for calcium flux analysis. Each drug was
incrementally added to the culture media to achieve a range of treatment concentrations and videos
were recorded immediately after each addition.

6.3

Reconstruction of time-series contraction waveforms

The workflow of our analytical approach started with video recording of purified beating hiPSCCMs, plated in standard 2D culture, using a bright-field or phase contrast microscope. The
recorded videos were subjected to motion tracking analysis to generate motion vectors that
measure the motion velocity and beat frequency. Motion tracking data was then decomposed using
PSR and from this, a set of dimensional parameters can be generated to reflect the dynamics of the
motions regarding to regularity and complexity (Figure 33). We then selected two motion
waveforms generated from video analysis using motion tracking software, one represented regular
cardiac contraction, while the other represented irregular (complex) cardiac contraction. Then, we
reconstructed these two motion waveforms into phase spaces, respectively (Figure 34a-d). For
each time lag, we can reconstruct a corresponding phase space through the time lagged method,
and the PSR evolved with the increase of time lag for each motion waveform. We selected the
PSR with τ = 15 for both motion waveforms and showed that the PSR for complex contractile
motion appeared to have higher degrees of convolution and eccentricity in comparison to the PSR
for regular motion (Figure 34a, c). This verified that distinct cardiac motion waveforms can be
represented in the phase spaces that were spatially distinguishable from one another.
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𝝉

Initial output parameters from the PSRs include the embedding (m), regularity (𝝆 = 𝒎), and
fractal (d) dimensions (Calculations supplied in Appendix A). The embedding and regularity
dimensions measure the overall rhythmic regularity of the gross peaks within a waveform, while
fractal dimension quantifies the complexity, which is a measure of the aberrations within the
system (Figure 34e-h). We compared the embedding dimension for the single waveforms of both
regular and complex motion by averaging all values over the entire variance of time lag. The
average embedding dimension for complex cardiac contractile motion was significantly greater
than the average for regular motion (Figure 34e), which translated to lower regularity dimensions
over all values of time lags (Figure 34f). We can utilize embedding and regularity dimensions to
measure and compare the motion regularity between two distinct waveforms. In contrast, the
fractal dimension quantifies the complexity of the waveforms. We found that the fractal dimension
was greater for complex contractile motion, which was consistent for all the time lags (Figure 34g,
h), inferring that larger values of fractal dimension reflect greater complexity of the time series.

6.4

Noise sensitivity of phase space reconstruction

To further characterize the different dimension parameters responding to the system aberrations,
we then applied random background noise ranging from 0-50% of the mean contraction velocity
to a signal. The addition of background noise generated random deviations within the original
motion waveforms, allowing us to study the influence of noise on the regularity and complexity
of the cardiac contractile motion. By visual inspection, the increasing increments of noise
introduced coarser aberrations within the signal, but the overall rhythmic regularity remained
conserved, as indicated by the identical gross contraction peaks (Figure 35a). The addition of
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random noise, therefore, didn’t influence the regularity of the motion, since the overall cardiac
beating rhythm wasn’t altered. Thus, the embedding and regularity dimensions remained constant
for all quantities of random noise (Figure 35b, c). Since noise creates variations in the signal, we
found that increasing levels of noise on the original signal led to an increase of fractal dimensions
(Figure 35d, e), which suggested that the fractal dimension is sensitive to noise and secondary
variations in the signal. Therefore, we can quantify the secondary aberrations as the system
complexity for the cardiac contractile motion.

6.5

PSR sensitivity to drug response

6.5.1

hiPSC-CM drug treatment

To investigate the ability of PSR method for quantifying the drug-induced cardiac motion
abnormalities, indicative of cardiac arrhythmia, we treated hiPSC-CMs with four drugs
(propranolol, E4031, metoprolol, and isoproterenol) known to influence cardiac beat rhythm and
motion. For each drug, we first recorded the videos of baseline control, then immediately treated
the hiPSC-CMs at two incremental drug concentrations and generated corresponding motion
waveforms using motion tracking software. By performing motion tracking analysis on the beating
videos, we analyzed the beat rate and maximum contractile velocity of the hiPSC-CMs treated
with different drug concentrations versus the baseline control. The beat rate was defined as beats
per minute based on frequency analysis of the motion waveforms, while the maximum contractile
velocity was defined as the average contraction peak magnitude based on amplitude analysis of
the motion waveforms. Next, we performed the PSR analysis on the motion waveforms and
computed the corresponding embedding, regularity and fractal dimensions.
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6.5.2

Propranolol

Propranolol, a beta blocker used to treat high blood pressure and post-myocardial infarction, has
been reported to induce arrhythmias by causing bradycardia. We observed abrupt arrhythmic
motion as a result of propranolol treatment. The resulting PSR analyses showed that, with respect
to propranolol (Figure 36), the average embedding dimension increased with increasing
propranolol concentration, which translated to a reduction of regularity dimension with higher
concentrations of propranolol. However, fractal dimensions have no significant difference between
baseline and two concentrations of propranolol, indicating propranolol treatment did not
dramatically influence the complexity of cardiac contractile motions.

6.5.3

E4031

E4031 is a hERG potassium ion channel blocker that prolongs the QT interval and result in lethal
arrhythmias. Treatment with E4031 (Figure 37), displayed increased embedding dimension and
decreased regularity dimension in response to the drug, which implied that E4031 induced
arrhythmic contractile motions. Furthermore, E4031 treatment induced an increase of fractal
dimension, especially for high dosage of the drug. This suggested that E4031 not only induced
arrhythmic motions, but also induced contractile aberrations to the hiPSC-CMs.

6.5.4

Metoprolol

Metoprolol is a beta blocker and is used to treat conditions that cause abnormally fast heart rate.
Metoprolol-induced arrhythmias (bradycardia) can occur at excessive dosages. Application of
metoprolol up to 40 µM resulted in no significant changes of contraction motion. Although
metoprolol falls within the same drug category as propranolol, it is a milder and less potent beta-
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adrenoceptor antagonist with lower effect of attenuating beat rate than propranolol149,150. Based on
the PSR analysis, there was no significant difference in either the embedding, regularity, or fractal
dimensions for all concentrations of the drug (Figure 38). This indicated that metoprolol does not
induce arrhythmic contractile motion on hiPSC-CMs based on PSR analysis, as this drug does not
significantly affect the regularity and the complexity of the system.

6.5.5

Isoproterenol

Lastly, isoproterenol is a beta adrenoceptor agonist that treats bradycardia. This drug can accelerate
the heart rate and potentially induce tachycardia. Application of isoproterenol significantly
changed the embedding and fractal dimensions with increasing concentration of drug (Figure 39).
In particular, the embedding dimension significantly decreased from the baseline control to a low
dosage (50 nM) of isoproterenol. However, as the drug concentration increased further to 10 µM,
the embedding dimension increased. This suggested that low concentrations of isoproterenol had
the therapeutic effect of rescuing arrhythmic contractile motions to more regular and consistent
motions. However, overdose of isoproterenol might cause the heart beating to lose its’ regular
rhythm. The average fractal dimension increased with isoproterenol treatment, indicating that the
contractile motion became more complex, partially due to the increase of beat rate.

6.5.6

Conclusions of PSR drug response

By analyzing the contractile motions of hiPSC-CMs exposed to these four drugs at different
concentrations, we found that frequency analysis (beat rate) and amplitude analysis (MCV) could
only prove the functionality of specific drug. For example, isoproterenol supposedly increased the
beat rate and contraction velocity, while E4031 decreased both parameters. The risk level of drug-
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induced arrhythmic motion was not well characterized solely relying on this analysis. However,
by performing PSR analysis on these waveforms, we were able to characterize the system
dynamics of the hiPSC-CMs contractile motion, and further compute their regularity and
complexity as quantifications of drug risk level. For example, exposure of E4031 at low dosage
would potentially induce arrhythmic contractile motion, while low dosages of isoproterenol could
help regulate the heart rhythm and diminish the arrhythmia.

6.6

Comparison of PSR responses to different assays of cardiac physiology

6.6.1

Calcium flux assay

Using GCaMP6f hiPSC-CMs, we validated the performance of the PSR algorithm on both optical
flow motion analysis and calcium flux analysis, one of the standard assays of cardiac
electrophysiology. GCaMP6f hiPSC line has been generated to visualize the calcium flux on the
living hiPSC-CMs without any fluorescent markers24,151. PSR analysis is not only limited to the
waveforms generated from the contractile motion tracking-based on the optical flow method. This
analytical algorithm can be also used to analyze the waveforms of electrophysiological signals
generated across a wide range of standard assays. By applying isoproterenol and propranolol to
GCaMP6f hiPSC-CMs, we generated the corresponding waveforms from motion tracking analysis
and the transient calcium flux (Figure 40a-c). We performed the PSR analysis on both contractile
motion data and calcium flux data to determine the arrhythmic-like behaviors responding to
different drug interference.

6.6.2

PSR responses of motion tracking in comparison to calcium flux
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Based on the PSR analysis coupled with optical flow motion tracking, GCaMP6f hiPSC-CMs
treated with isoproterenol showed an improvement in regularity (low embedding dimension and
high regularity dimension) at a 10 nM drug concentration (Figure 40d). This trend was validated
in the PSR analysis coupled with the calcium flux measurement, where we also observed low
embedding dimensions and higher regularity upon exposure to the drug. This indicated that both
approaches are sensitive to changes in the regularity of the system. We also observed increased
fractal dimensions in response to 10 nM isoproterenol treatment from PSR coupled with motion
tracking. However, this did not match with the calcium flux analysis, where we observed an overall
fractal dimension decrease, indicating that physical contractions and electrophysiology represent
different complexities in the cardiac physiology. By treating GCaMP6f hiPSC-CMs with
propranolol at 10 µM (Figure 40e), we observed a significant increase in the embedding
dimensions from the PSR algorithm coupled with both motion tracking and calcium flux. We also
found a significant increase of fractal dimensions with the 10 µM propranolol addition from the
PSR analysis of both assays. Thus, both assays coupled with PSR showed that treatment of
propranolol reduced the regularity and subsequently enhanced the complexity of the cardiac
physiology. These results indicated that electrophysiological assays coupled with PSR analysis not
only validated our optical flow method, but also served as complimentary assessment for future
multiplexed drug-induced arrhythmia analysis.

We have determined that PSR analysis can be applied to two different approaches (contractile
motion tracking and calcium flux measurement) for in vitro assessments of hiPSC-CM arrhythmic
potential. To further compare the sensitivities of each assay to the drug interference when coupled
with PSR algorithm, we performed statistical analyses (t-tests) on the PSR outputs (embedding
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and fractal dimensions) for the drug-treated hiPSC-CMs relative to baseline controls. We then
cross-examined the p-values of the PSR data generated from motion tracking with those generated
from calcium flux measurement. For GCaMPf6 hiPSC-CMs treated with isoproterenol, the pvalues computed from the embedding dimensions was less for motion tracking, compared to the
calcium flux (p<0.0001 vs. p=0.0003). This was also consistent with the embedding dimensions
calculated from propranolol treatment, where the p-values were p<0.0001 and p=0.0276 for
motion tracking and calcium flux, respectively. For isoproterenol treated hiPSC-CMs, the p-value
of the fractal dimensions was found to be larger for motion tracking (p=0.01) compared to the
calcium flux (p<0.0001). From the propranolol treatment, the p-values of fractal dimensions
between the motion tracking and calcium flux were comparable (p<0.0001).

The smaller p-values calculated from the embedding dimensions coupled with motion tracking, a
consistent trend between both drugs, indicated that the PSR regularity quantification is more
sensitive to the physical contraction recorded using the motion tracking approach. P-values from
analysis of the fractal dimension were found to be comparable between the motion tracking and
the calcium flux assays of propranolol treatment. This suggests that the quantification of system
complexity is equally sensitive to both assays, However, this was not consistent with isoproterenol
treatment, where complexity computation was found to be more sensitive to the calcium flux (as
indicated by the smaller p-value). This inconsistency was attributed to our previous observation,
where the electrophysiology and the physical contraction represented different system
complexities.

6.7

Nonlinear characterization of contractile complexities
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6.7.1

Complexities represented by capacity and correlation dimensions

The capacity and correlation dimensions are additional measures of complexity that complement
the previously described fractal dimension. In order to determine the complexity of cardiac
contractile dynamics, we performed PSR of the contractile motion waveforms recorded from
hiPSC-CMs. To analyze the fractal properties of reconstructed phase space, we can compute
capacity and correlation dimensions based on different methods (Figure 41a). After hiPSC-CM
purification, we recorded the beating videos of hiPSC-CM clusters (Figure 41b), and compared
the difference in both linear and nonlinear parameters between two independent tissue cluster
samples (Cluster A vs. Cluster B). Motion waveforms corresponding to Cluster A and Cluster B
were visibly comparable based on visual inspection (Figure 41c), which was corroborated with
similar motion results (Table 4), including comparable beat rates (33.17 vs. 33.99 beats per
minute), contraction velocities (24.65 vs. 22.46 µm/s), and relaxation velocities (18.69 vs.19.97
µm/s). Based on these two motion waveforms, the peak-to-peak (PP) interval was also computed
as a traditional linear assessment. Similarly, the average PP interval remained relatively consistent
between both samples (1.81 vs. 1.77 seconds). Therefore, from motion tracking analysis, we
concluded that these two samples exhibited similar contractile features based on linear time series
analysis.

Nonlinear PSR analysis was then applied to extend the characterization of these two contraction
motion waveforms (Figure 41d, e). The raw data acquired from motion tracking analysis was
processed using custom algorithms, from which we were able to calculate the capacity and
correlation dimensions based on time lag (τ) and embedding dimension (m), respectively. The
mean capacity dimension (Dcapacity) was also similar between two samples (1.354 vs. 1.350) (Figure
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41d), inferring that the geometrical capacity of phase space between two clusters was comparable.
We also calculated and plotted the correlation dimension (Dcorrelation) with respect to embedding
dimension, which is a measure of the dynamic distribution of points in the phase space (Figure
41e). In contrast, Cluster B exhibited a greater steady correlation dimension (1.193 vs. 1.354).
Therefore, the correlation dimension was able to detect the contrasts in system dynamics of the
nonlinear plots between two samples exhibiting similar contractile behaviors. Computation of the
correlation dimension provided quantification of additional aspect of the system dynamics, which
were not visibly apparent in the motion waveforms as well as not reflected in the capacity
dimension.

6.7.2

Drug response

To investigate the capability of our new analytical approach to evaluate the responsiveness of
hiPSC-CMs to drug interference, hiPSC-CMs were exposed to three drug compounds (alfuzosin,
flecainide and isoproterenol) known to modulate heart contractile behaviors. (Figure 42 and Figure
43). For this study, we recorded the beating videos for both untreated baseline controls and drugtreated hiPSC-CMs over short- and long-term drug exposure. For short-term dose-response
assessment, hiPSC-CMs were treated with incremental doses of specific drugs and subsequently
recorded as beating videos following each dosage. The videos were then analyzed with motion
tracking to generate the corresponding waveforms (Figure 42a-c) and followed with nonlinear
dimensional analysis. Alfuzosin is an alpha-adrenergic blocker prescribed to treat benign prostatic
hyperplasia152. However, alfuzosin use has also shown adverse effects on prolongation of QT
interval by delaying cardiac repolarization152. Treatment with alfuzosin significantly increased the
beat rate of hiPSC-CMs but with negligible change in average contraction velocities (Figure 42d).

98

Nonlinear analysis showed insignificant changes in capacity dimension with increasing dose.
Alternatively, the drug treatment at both the 1 nM and 100 nM concentrations resulted in an
observable decrease of the correlation dimension relative to the baseline control (Figure 43a).
Next, hiPSC-CMs were treated with flecainide, which is a sodium ion channel blocker and is
prescribed to restore normal heart rhythm from arrhythmias153. In contrast to alfuzosin, the
introduction of flecainide caused a decrease in the beat rate, with slight, but insignificant increases
in contraction velocities (Figure 42e). This corresponded to insignificant variations in capacity
dimension and correlation dimension with each incremental dose (Figure 43b). Lastly, we treated
the hiPSC-CMs with isoproterenol, which is a potent β adrenergic agonist that is used clinically to
treat bradycardia. hiPSC-CMs treated with isoproterenol had significantly greater beat rate and
contraction velocities (Figure 42f), as well as higher capacity and correlation dimensions (Figure
43c).

For the long-term drug exposure study, hiPSC-CMs were treated continuously with a constant dose
(10 nM) of isoproterenol for 7 consecutive days, wherein the drug supplemented media was
changed every two days and videos were recorded daily. Throughout the entire treatment period,
the average contraction velocities of the tissues remained relatively consistent (Figure 42g, h).
Regarding contraction frequency, a significant increase in beat rate was found only after the first
hour of treatment. Subsequent days after, the contractile physiology returned to the baseline level,
indicating desensitization of the hiPSC-CMs to the drug. The reduced sensitivity can be attributed
to the fact that hiPSC-CMs are still physiologically immature with limited responsiveness to β
adrenergic stimulation30,154. Regardless of the drug-induced changes to contractile physiology, the
capacity dimension remained consistent with insignificant fluctuations, after the initial hour and
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over the 7-day period. In contrast, the correlation dimension exhibited significant variation only
towards the last two days of treatment (Figure 43d).

6.8

Conclusions and discussion

A combination of optical flow-based motion tracking and PSR analysis was used to characterize
and quantify the arrhythmic behavior of cardiac contractile motion. In this chapter, we
reconstructed 1D time series of contractile motion waveforms obtained from optical flow analysis
of hiPSC-CMs into a multi-dimensional phase space. Using nonlinear phase space reconstruction,
we distinguished the different biological dynamics based on the embedding, regularity and fractal
dimensions. These analyses were supplemented to traditional linear approaches to characterize
contractile dynamics exhibited by hiPSC-CMs. Based on PSR analysis, we evaluated the druginduced arrhythmic contractile motion from hiPSC-CMs and concluded that the regularity and
complexity of cardiac contractile motion changes in response to the drugs.

The development of signal processing techniques in biomedical research remains a priority in order
to diagnose and treat patients sooner. Because of its’ increasing recognition in clinical settings, we
have extended phase space reconstruction signal analysis to in vitro cardiac model systems for
characterizing the cardiac signals obtained from hiPSC-CMs. Implementation of optical-flow
based motion tracking to hiPSC-CMs has allowed us to quantify the variations in contractile
physiology, providing a linear time domain assessment of beat rate and contraction velocity. The
essential effort of this work is to reconstruct these time series of experimental data into a multidimensional phase space for nonlinear analysis on the contractile dynamics of hiPSC-CMs,
providing a quantitative measure of in vitro system complexities. We envision that this integrated
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approach can potentially be useful for health monitoring and diagnostics, such as assessment of
heart rate variabilities and for early predictions of disease onset. In addition, the application of this
analytical toolbox in pharmacological cardiotoxicity is essential to better understand drug effects
on cardiac health that are not readily apparent and cannot be observed through time domain cardiac
signals.

101

Figure 33. Process workflow of hiPSC-CM contractile motion characterization. The
contractile motion of hiPSC-CMs was recorded as beating videos, which were analyzed using
motion tracking software to generate motion vectors and contractile motion waveforms. This data
was then analyzed using PSR to compute the dimensional parameters. The embedding dimension
characterizes the regularity of the contractile motions, which reflects the changes in beat rhythm
and overall gross motion. The fractal dimension characterizes the complexity, which reflects the
secondary aberrations present within each beat cycle128.
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Figure 34. Reconstruction of cardiac motion waveforms into phase space. The phase spaces
of a regular (a) and a complex (c) cardiac contractile motions are plotted along with their
corresponding motion waveforms (b, d). The embedding dimensions from a single motion
waveform were computed from PSR to compare the differences in regularity between two
contractile motions (e). The regularity dimensions derived the embedding dimensions were plotted
with respect to τ (f). The average fractal dimension across all τ was computed from PSR (g) and
then plotted with respect to τ (h)128.
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Figure 35. PSR analysis of secondary system aberrations. A motion waveform was supplied
with random noise ranging from 2.5%-50% (a), and corresponding phase space was reconstructed
to compute the dimensional parameters respectively for different degrees of noise. No significant
difference was found based on embedding and regularity dimensions among the contractile
motions with different noise level (b, c), but fractal dimensions exhibited significant increase with
the increase of the noise level (d, e)128.
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Figure 36. PSR analysis of propranolol treated hiPSC-CMs. The application of propranolol to
hiPSC-CMs increased the average embedding dimension with the increase of drug concentrations,
which correlated to a reduction in regularity dimension. No significant difference was found for
fractal dimension between baseline control and drug exposure128.
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Figure 37. PSR analysis of E4031 treated hiPSC-CMs. E4031 induced significant increases in
the embedding and regularity dimensions between controls and drug exposure. High dosage of
E4031 (100 nM) induced a significant increase of fractal dimension on the hiPSC-CMs in
comparison to the control and low dosage128.
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Figure 38. PSR analysis of metoprolol treated hiPSC-CMs. PSR analysis showed that treatment
of hiPSC-CM with metoprolol has no significant influence on the embedding, regularity and fractal
dimensions128.

107

Figure 39. PSR analysis of isoproterenol treated hiPSC-CMs. Low dosage of isoproterenol (50
nM) decreased the embedding dimension, which corresponded to a rise in the regularity of the
system. In contrast, high dosage of isoproterenol (10 µM) increased the embedding and fractal
dimensions, indicating the contractile motions of hiPSC-CMs gained aberrations but lost
regularity128.
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Figure 40. Drug-induced arrhythmia comparison of motion tracking versus calcium flux.
Brightfield and fluorescence videos of drug-treated GCaMP6f hiPSC-CMs were recorded for (a)
motion tracking analysis and (b) calcium flux analysis. (c) Waveforms generated from each assay
were subjected to PSR analysis. PSR analysis of both methods illustrated the sensitivities to drug
interference by quantifying changes in the embedding and fractal dimensions as a result of (d)
isoproterenol and (e) propranolol induced-arrhythmias128. All scale bars are 100 μm.
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Figure 41. Nonlinear reconstruction of time series contractile motion signals.(a) Contraction
motion waveforms were analyzed using phase space reconstruction to determine the fractal
properties of the signals, including two parameter capacity dimension and correlation dimension,
which characterize the geometric space and distribution dynamics of the signals. (b) Two hiPSCCM clusters (Cluster A and Cluster B) exhibiting comparable contractile physiology, (c) which
were compared in time domain and respective nonlinear phase spaces. (d) The capacity dimension
with respect to time lag (τ) was comparable between the two clusters, (e) but the correlation
dimension with respect to embedding dimension (m) showed different trends129. Scale bars = 100
μm.
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Table 4. Comparison of linear and nonlinear parameters of Cluster A and Cluster B129.
Cluster A

Cluster B

Beat Rate (BPM)

33.17 ± 0.349

33.99 ± 0.227

Peak-Peak Interval (s)

1.81 ± 0.016

1.765 ± 0.012

Contraction Velocity (µm/sec)

16.02 ± 0.187

14.599 ± 0.143

Relaxation Velocity (µm/sec)

12.15 ± 0.075

12.98 ± 0.142

Mean Capacity Dimension

1.354

1.350

Steady Correlation Dimension

1.193

1.354
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Figure 42. Contractile velocities of hiPSC-CMs exposed to drug compounds. Short term
changes to contraction motion waveform and average contraction velocities were observed in
hiPSC-CMs treated (a, d) alfuzosin, (b, e) flecainide and (c, f) isoproterenol. (g, h) Long-term
treatment of hiPSC-CMs with isoproterenol showed negligible changes in both contraction and
relaxation velocities over a 7-day period129.
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Figure 43. Fractal changes on hiPSC-CM drug response. hiPSC-CMs was treated with 3 drugs,
including (a) alfuzosin, (b) flecainide and (c) isoproterenol over a short period with incremental
doses. The beat rate, capacity dimension and correlation dimension were compared respectively
in response to the drug dosages. (d) A long-term drug study was also conducted by supplying a
constant dose of isoproterenol over the course of 7 days129.
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7. Chapter 7: Summary

Conclusions
This dissertation discusses engineering and development of novel tools and methodology to model
heart development and characterize cardiac physiology for advanced diagnostic capabilities,
especially for drug-induced cardiotoxicity. This dissertation primarily focused on engineering
cardiac organoids using micropatterning to govern the organoid cell assembly and tissue
differentiation. In Chapter 3, we exploited how pattern geometry, such as shape and size,
influences 3D cardiac tissue formation and cardiac contractile functions to optimize the organoid
engineering. In Chapter 4, we applied the cardiac organoid platform as an embryotoxicity
screening assay to evaluate the potential of this platform as an alternative in vitro screening method
for developmental toxicity. Chapter 5 explores the cardiac organoid cellular composition using
high resolution single-cell genomics and bioinformatics analysis. Lastly, Chapter 6 discusses a
novel computational tool based on nonlinear phase space reconstruction to quantitatively
characterize cardiac contraction functions of engineered cardiac tissue, especially for drug-related
cardiotoxicity. This work illustrates the engineering, application, and characterization of cardiac
organoids based on micropatterning technology as well as novel methods for cardiotoxicity drug
screening. We envision that this work will provide opportunities to advance cardiovascular
research through novel use of tissue engineering and computational approaches.

7.1 Geometric confinement on cardiac organoid development
Chapter 3 exploited how pattern geometry influences cardiac organoid tissue differentiation,
structure, and contractile function. Pattern shape significantly influences the ability of the
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patterned hiPSCs to differentiate into robust cardiac tissue. Circular geometry produced cardiac
organoids with the largest cardiac tissues based on 3D architecture and cardiac tissue area fraction,
which was proportional to the contraction velocity. When organoid differentiation was performed
in polygonal triangles and squares, the contracting cardiac tissues became smaller with a larger
fraction of smooth muscle-like stromal cells relative to the circular organoids. This suggested that
the biophysical stresses of the sharp corners of polygonal geometries promotes the differentiation
into stromal cells. In addition, pattern size proved to be a limiting factor in the 3D morphogenesis
of the cardiac organoids, where parameters of 3D architecture peaked at mid-sized (600 μm)
patterns. This work not only illustrates the versatility in organoid engineering via micropatterning,
but also how researchers can use micropatterning to tailor and fine-tune stem cell organoids using
biophysical confinement.

This work can be expanded through additional comprehensive functional screenings. For instance,
screening of transient calcium is a common tool to study cardiac contraction, as intracellular
calcium flux is directly correlated to a muscle contraction. Using GCaMP6f hiPSC lines, we can
generate cardiac organoids for an integrated analysis of contraction motion with transient calcium
for a more comprehensive view of relationships between organoid structure-function and organoid
engineering parameters.

7.2 Cardiac organoids as an embryotoxicity screening platform
Chapter 4 assessed the potential applicability of cardiac organoids as an embryotoxicity platform.
Since the organoids are generated from the self-assembly of differentiating hiPSCs, we
hypothesized that this process could recapitulate in vivo heart development. This would potentially
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alleviate current limitations in fetal drug toxicity testing and provide safer alternative in medication
prescribing decisions for pregnant women. Upon exposure to a variety of drugs ranging in safety
classification, we found that the cardiac organoid formation was sensitive to continuous drug
exposure, especially for well-known toxic drugs, such as thalidomide (category X). Contrastingly,
the organoids were not affected by well-known safe drugs, such as doxylamine succinate (category
A). The organoids also showed varying toxicity for drugs with safety classifications ranging in
between doxylamine succinate and thalidomide, with increasing toxicity as we tested drugs along
the pregnancy drug classification spectrum. In addition, toxicity was manifested as impairments
that were unique to each drug. These studies showed that this cardiac organoid platform not only
is sensitive to drug exposure, but it can also classify developmental toxicity to identify cellular
developmental processes that the drug is targeting.

Through this work, we have established that cardiac organoid development is sensitive to drug
exposure, which is manifested as structural and/or functional impairment. As a potential model for
human heart development, this work can be expanded to study the chamber development over
time. By integrating time-lapse microscopy, we can identify events in organoid development that
are targeted by drug compounds and correlate these events with human organogenesis.
Furthermore, integration of genomic characterization through PCR and RNA sequencing can
reveal specific drug pathway targets.

7.3 Single cell characterization of cardiac organoids using next generation sequencing
technologies
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Chapter 5 explored the cardiac organoid composition using single cell genomics. Based on the
bioinformatics analysis, cardiac organoids were interestingly composed of approximately 10 cell
types along three trajectory lineages: cardiac, stromal, and endodermal. We then evaluated the
influence of geometric confinement on organoid lineage specifications by generating organoids in
small (200 µm), mid-size (600 µm), and large (1000 µm) circle patterns. Cardiac organoids
generated from very small patterns (200 µm) were primarily composed of less definitive and
premature cells indicative of progenitor cell types. Cardiac and smooth muscle cell specification
was optimal in mid-sized 600 µm organoids and that larger sizes (1000 µm) drives the organoid
specification to endodermal cell lineages. This study not only demonstrated the importance of size

restraint on organoid engineering but also how engineering parameters heavily influence cell fate
specification. Understanding the cellular diversity that make up the cardiac organoids will advance
organoid research by providing a more integrated and comprehensive evaluation of organoid
function and structure based on individual cell contributions as well as overall cell composition.
In addition, this data can provide insight on biological regulatory mechanisms involved in human
development via biophysical cues, allowing us to better understand the role potential biophysical
factors in vivo on organ development.

In order to correlate organoid genomics with organ development, future work will require genomic
and bioinformatics analysis of cardiac organoids over time. Therefore, future work includes
bioinformatics processing of organoids at various timepoints throughout differentiation. Our
differentiation targets will include timepoints before and after small molecule introductions. This
will allow us to understand which developmental pathways are being targeted by the small
molecules and correlate these developmental events with genomic datasets of target organs
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provided on public databases. For instance, we aim to compare our organoid development with in
vivo mouse heart development as well as liver development based on the trajectories that were
revealed in Chapter 5.

7.4 Quantitative characterization of drug-induced cardiac arrhythmias using nonlinear
computational tools
Chapter 6 discussed the development and application of a signal processing workflow to
characterize contraction physiology of hiPSC-CMs, particularly for drug screening applications.
Phase space reconstruction and nonlinear analytical toolboxes were used to analyze contraction
motion and distinguish biological signal dynamics based on various nonlinear variables. hiPSCCMs treated with various drugs influencing heart rhythm showed changes in signal regularity and
complexity in response to these drugs, demonstrating the application of the analytical workflow in
drug screening for cardiotoxicity. The development of signal processing techniques in biomedical
research remains a priority in order to diagnose and treat patients sooner and more precisely. The
essential effort of this work is to reconstruct these time series of experimental data into a multidimensional phase space for nonlinear analysis on the contractile dynamics of hiPSC-CMs,
providing a quantitative measure of in vitro system complexities. We envision that this integrated
approach can potentially be useful for health monitoring and diagnostics, such as assessment of
heart rate variabilities and for early predictions of disease onset.

We envision that this work can have wide applications, as the algorithms are versatile and can be
applied to any type of cardiac signal. The work in Chapter 6 demonstrated the applicability to
studying the drug response of cardiac contraction signals. Therefore, this can be implemented to
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work that was discussed in Chapter 3 and Chapter 4, which discuss biophysical and drug-related
influences on cardiac contractile functions. In addition, our lab is currently exploring machine
learning methods to provide a comprehensive and systematic view of structure-function
relationships of cardiac organoids. Using machine learning to integrate the nonlinear metrics with
standard assays of cardiac organoid function will allow us to better understand cardiac physiology
with much larger scale datasets, which will facilitate better prediction of drug-related
cardiotoxicity.
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Appendix

Appendix A: Calculation of phase space reconstruction parameters
A.1 Computation of the embedding, regularity, and fractal dimensions
The principle of this approach is to transform the properties of a time series into topological
properties of a geometrical object embedded in a space, in which all possible states of the system
are represented and each state corresponds to a unique vector 155. Mathematically, the states of a m
dimensional dynamic system can only be characterized by m independent quantities that represent
the coordinates of the phase space. Unfortunately, this representation is not possible for
experimental data, because it is a 1D time series. Starting on the conjecture that all groups of m
values should give equivalent results, it is then possible to construct m-vectors that contain the
same information as the original state vectors: this is the principle of the time lagged method 156,
which simply takes m consecutive elements of the time series directly as coordinates in the phase
space. The challenge is to find the appropriate number m, such that the properties of the initial time
series are kept in the reconstructed space. A method consisting of building a m dimensional system
from a 1D time series with a fixed delay to shift the original data (time lagged method) has been
introduced by Takens156.

Let be the system states with a normalized sample step T = 1, τ !ℕ∗ , while 𝑖 = 1, 2, … 𝑛 are the
indices of the successive samples values of the cardiac contraction motion waveform s:
𝑉(𝜏, 𝑚) = [𝑆⃗(𝑖), 𝑆⃗(𝑖 + 𝜏), … 𝑆⃗(𝑖 + (𝑚 − 1)𝜏)],

(1)

where V is a matrix containing the phase space vectors:
121

𝑠(1)
⎡
⎢
𝑠(1 + 𝜏)
⎢
⎢
.
⎢
𝑉(𝜏, 𝑚) = ⎢
.
⎢
⎢
.
⎢
⎢
⎣𝑠(1 + (𝑚 − 1)𝜏)

𝑠(2)

...

𝑠(2 + 𝜏)

...

.

...

.

...

.

...

𝑠(2 + (𝑚 − 1)𝜏)

...

𝑠(𝑁 − (𝑚 − 1)𝜏)

⎤
⎥
𝑠(𝑁 − (𝑚 − 2)𝜏)
⎥
⎥
.
⎥
⎥
.
⎥
⎥
.
⎥
⎥
𝑠(𝑁)
⎦

(2)

Next, Takens theorem156 gives conditions under which a nonlinear dynamical system can be
reconstructed from a sequence of observation of its states. The state space vectors are obtained
from the sample signal according to the embedding dimension m and the time delay τ. The
embedding dimension m is computed for each time delay τ based on False Nearest Neighbor
(FNN) method, and resulting phase space vectors obtained from (1) are:

𝑉(1, 3) = @𝑆⃗(𝑖), 𝑆⃗(𝑖 + 1), 𝑆⃗(𝑖 + 2)A,

(3)

𝑉(3, 3) = @𝑆⃗(𝑖), 𝑆⃗(𝑖 + 3), 𝑆⃗(𝑖 + 6)A,

(4)

𝑉(6, 3) = @𝑆⃗(𝑖), 𝑆⃗(𝑖 + 6), 𝑆⃗(𝑖 + 12)A,

(5)

𝑉(9, 2) = @𝑆⃗(𝑖), 𝑆⃗(𝑖 + 9)A,

(6)

The phase space reconstruction is influenced by the parameter time lag τ. If τ is too small, the
trajectories of 𝑆⃗(𝑖) and 𝑆⃗(𝑖 + 𝜏) are close to one another, potentially making it indistinguishable
and creating redundant coordinates. This implies that the trajectories of attractor projected on the
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two axes are not correlated, which makes the phase space reconstruction useless. For this reason,
the basic criterion for choosing τ should be the largest value of τ resulting coordinates relatively
independent. Without prior knowledge of the system, especially for experimental data, properly
determining this parameter is not apparent. Therefore, in this study, for cardiac contraction motion
waveforms, the time lag τ has been varied form τ = 1 - 50.

To estimate the embedding dimension m, we used FNN method, where the best value of m
corresponds to the minimum value of m for which the FNN is close to zero 157. From a geometrical
point of view, the time series (experimental measurements) is the projection of a m dimensional
system to a 1D space. Therefore, two points in a m dimensional space, even far from each other,
could be very close (and even be superimposed) in the original 1D space. These points are called
false neighbors. If m is not large enough, the state vectors on the trajectories could be very close
with possibility of intersections between the trajectories of the attractor, which will result in a
reconstructed space totally different from the original one. A higher value of m, theoretically, is
possible by just creating a larger space that contains minimal space. However, this will cause
redundant problems and inefficiency issue, as it requires significantly strong computation power.
The main idea behind this method is to determine an appropriate value of m as follows:
• We begin the reconstruction with vectors of delay 𝑆⃗(𝑖) of dimension m small
enough;
• We determine the neighbors of eachDDD⃗
𝑆(𝑖) by checking E𝑆⃗(𝑗) − 𝑆⃗(𝑖)E ≤ 𝜀, where 𝜀
is a length appropriate to the problem and containing the number of these
neighbors;
•

We increase m until the neighbor numbers stabilize.
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To quantify the regularity of the time series of cardiac contraction waveform, we introduce a new
parameter called “Regularity Dimension” noted as 𝜌, which is defined as:
$

𝜌=%

(7)

To quantify the complexity of time series of cardiac contraction waveform, we computed the
fractal dimension d using Boxcount method and Variation estimator. In the case of Boxcount
method, it is supposed that the original time series graph is fully covered by a box. The box is
divided into four sub-boxes, for example. The number of boxes needed to cover the entire time
series is counted. Following the same rule, these sub-boxes are divided into smaller boxes. The
different box sizes (𝛼) (also called scales) and the number N of validated boxes are recorder. The
slope of the curve logN(𝛼) versus log(𝛼) gives the fractal dimension.
𝑑 = lim log
&→(

)(&)

(8)

!
"

,-./ 0

The “Variation estimator” is based on the 2nd order Variogram of a stochastic process as
described in 158,159. In this case, a fractal dimension is computed for each value of the time lag τ.

A.2 Characterizing nonlinear complexity via Capacity and Correlation Dimensions
The capacity dimension of contraction motion waveforms was calculated using the variogram
method based on a “variation estimator”158. The variation estimator plots the variance γ (𝜏) of
values given for the points separated by a certain distance 𝜏, given by
2

N
1
⎡S
⎤
γ (τ ) =
−S
∑
2(N − τ ) i=τ ⎣ (i+1:N ) (1:N −i ) ⎦

(1)

where N is the number of neighboring data points within the time lag distance specified, Si+1:N is
the value of the initial point, and S1:N-i is the value of the neighboring point being compared in the
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range of i bounded by the time lag distance 𝜏 and the length N of the contraction motion waveform
S. Thus, for computing capacity dimension using variogram approach, first step is to compute the
variance γ(𝜏) for different time lag 𝜏. This can be plotted as a curve, in which the variogram value
increases with time lag to a maximum, and levels off at a time lag where the total variability of the
data field is reached. Next, log(γ(𝜏)) vs. log(𝜏) is plotted, and regression method is used to calculate
the slope P of the line. Finally, the capacity dimension is given by
𝐷12321456 = 2 − 𝑃/2

(2)

The correlation dimension (Dcorrelation) measures the geometrical complexity of an attractor160
and has become a standard measure of the fractal properties of attractors that have been
reconstructed in the state space. A larger value of the correlation dimension depicts a higher degree
of complexity in the signal dynamics. If the dynamics is stochastic, D tends to infinity and the
attractor is obtained when the signal is embedded in a phase space. From a cardiac contractile
motion waveform (Sn; n = 1, …, N) with N samples, considering Takens theorem156, an mdimensional phase-space is constructed as follows:

𝑥
DDD⃗7 = U𝑆8 , 𝑆89$ , 𝑆89:$ , … , 𝑆89(%;<)$ V

(3)

𝑗 = 1, … , 𝑁 − (𝑚 − 1)𝜏

The phase space reconstruction depends on two parameters: time lag τ and embedding dimension
m. If τ is too small, the trajectories of Sj and Sj+τ are too close to be separated. In contrast, if τ is
too large, the trajectories of attractor projected on the two axes are not correlated, which makes
the reconstructed phase space useless. The goal is to find the smallest value of τ to ensure the
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independence of resulted coordinates in the phase space. Herein, the time lag τ is computed using
the method of autocorrelation function (ACF)161, and it corresponds to the time required for the
ACF to decrease to 1/e of its original value as follows:
𝐶(𝜏) = 𝐶(0)𝑒 ;=$
where C(0) is calculated without a time lag (τ = 0). τ can be defined when 𝐶(𝜏) =

(4)
>(()
?

(where k =

1/τ), which corresponds to the time required for the ACF to decrease to 1/e of its original value.

In terms of the embedding dimension m, a well-defined embedding dimension is essential to a
phase space to describe all possible states of a dynamic system. Since the dimension of the phase
space reconstructed from experimental data is not known in priori, embedding dimension m will
be determined to ensure that reconstructed phase space is topologically identical to original data.
From a geometrical point of view, the time series (experimental data) is the projection of a mdimensional system (reconstructed phase space) to a one-dimensional space. Therefore, two points
in the m-dimensional space, even far from each other, could be very close in the original 1D space,
which makes them false neighbors. In the reconstructed phase space, the distances between a point
and its nearest neighbor will be measured. If two points are real nearest neighbors, the distance
will not change with the increase of dimension. Herein, the embedding dimension m is estimated
using the method of False Nearest Neighbors (FNN)162, where the optimal value of m corresponds
to the minimum value of m for which the FNN is close to zero.

In our work, the correlation dimension is determined using the Grassberger-Procaccia method163,
based on the following approximation: the probability of having a couple of points in a box of size
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r is equal to the probability of having a couple of points with separation distance less than r when
𝑟 → 0. The correlation dimension is defined by:

,-.DE# (A)F

𝐷1@AA?B254@C = lim \
A→(

,-.(A)

]

(5)

where the correlation integral Cm(r) is approximately given by:

:

𝐶% (𝑟) ≈ )();<) ∑)
8G<,4I8 𝛩(𝑟−∥ 𝑥8 − 𝑥4 ∥)

(6)

where Θ(x) is the Heaviside step function. The summation counts the number of pairs (xi xj) for
which the distance || xi, xj || is less than r. For each reconstructed phase space trajectory, the
distances between all points in the trajectory are calculated. The logarithm of the smallest distance
(represented by rmin) and the logarithm of the largest distance (represented by rmax) are then
computed. A series of bins is created to record the correlation sum, Cm(r), which is the normalized
number of couples of points with a separation distance less than a specified distance r. The process
of depositing counts of data into bins is analogous to recording counts of the occurrence of events
within data in a frequency histogram. In this study, an arbitrary number of 32 bins is used and the
width of each bin is set to
C(A$%& ;A$'( )
J:

A$%& ;A$'(
J:

.Thus, from first to last, the separation distances 𝑟C = 𝑟%4C +

, where n = 1 to 32 are considered. In practice, the correlation dimension is obtained

from the slope of log (Cm(r)) versus log (r). Several Cm(r) are computed for increasing values of
the embedding dimension m, and the slopes are determined from a scaling region of the log-log
plot. When m increases, Dcorrelation reaches to a saturation value corresponding to a steady
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correlation dimension164,165. From the distribution of the correlation dimension values, the
averaged value of the correlation dimension of this set is computed. Based on the curvature of
Dcorrelation values, the steady correlation dimension corresponding to the curve plateau was
computed for each set of Dcorrelation.
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